A Review of Plant Extracts and Plant-Derived Natural Compounds in the Prevention/Treatment of Neonatal Hypoxic-Ischemic Brain Injury

Hadi Mohsenpour 1, Mirko Pesce 2-*, Antonia Patruno 2-*, Azam Bahrami 3, Pardis Mohammadi Pour 4 and Mohammad Hosein Farzaei 3, *

Abstract: Neonatal hypoxic-ischemic (HI) brain injury is one of the major drawbacks of mortality and causes significant short/long-term neurological dysfunction in newborn infants worldwide. To date, due to multifunctional complex mechanisms of brain injury, there is no well-established effective strategy to completely provide neuroprotection. Although therapeutic hypothermia is the proven treatment for hypoxic-ischemic encephalopathy (HIE), it does not completely change outcomes in severe forms of HIE. Therefore, there is a critical need for reviewing the effective therapeutic strategies to explore the protective agents and methods. In recent years, it is widely believed that there are neuroprotective possibilities of natural compounds extracted from plants against HIE. These natural agents with the anti-inflammatory, anti-oxidative, anti-apoptotic, and neurofunctional regulatory properties exhibit preventive or therapeutic effects against experimental neonatal HI brain damage. In this study, it was aimed to review the literature in scientific databases that investigate the neuroprotective effects of plant extracts/plant-derived compounds in experimental animal models of neonatal HI brain damage and their possible underlying molecular mechanisms of action.

Keywords: hypoxic-ischemic encephalopathy; neonatal hypoxic-ischemic brain damage; birth asphyxia; perinatal hypoxia-ischemia; neonates; newborns; neuroprotective; plant extracts; natural compounds

1. Introduction

Hypoxia-ischemia (HI) is regarded as one of the major drawbacks of brain damage in the neonates and infants. Neonatal hypoxic-ischemic brain damage (HIBD) (synonymous with hypoxic-ischemic encephalopathy (HIE)) is the main drawback of newborn deaths and irretrievable and long-lasting neurodevelopmental disabilities in the sufferers [1]. HIE complications estimate 23% of infant deaths all over the world, and have impacted 0.7–1.2 million newborns per annum [2]. Cerebral palsy, epilepsy, mental retardation, motor and cognitive deficits, learning and behavioral disabilities, and other severe neurological disorders were regularly observed in the sufferers based on brain injury grade [3,4]. In infants with mild HIE, the death probability is 10% and the risk of neurodevelopmental disorders is 30%, while 60% of infants with severe HIE are at risk of death and all sufferers risk exposure to remarkable disabilities.

The neonatal HI (NI) incidence is near 1–8 of every one thousand live full-term births in developed countries, and nearly 25 in one thousand live full-term births in developing
Lately, advanced neonatology has evidenced a great improvement in survival of seriously premature newborns. The rate of incidence in the very low birth weight infants is 60% of all live births.

NHI commonly occurs as a result of prenatal or birth asphyxia near the time of birth [7,8]. The ordinary birth process that is correlated with asphyxia and severe asphyxia may affect a pre-existing normal brain, prompting acute encephalopathy. Severe asphyxia can arise for numerous causes, including abnormal uterine contractions, abruption of the placenta, umbilical cord compression, or failure of the neonate to initiate breathing successfully. Infection, growth retardation, and fever can enhance the brain sensitivity to nonpathogenic asphyxia. On the other hand, the prematurity subject is even more complicated which is frequently concomitant with impaired fetal growth and infection. Also, the general handling of the severe premature infants causes bases of postnatal insults. The most common form of perinatal injury is systemic asphyxia, which impacts the neonate/fetus cardiovascular system and results in a hypoperfusion by hypoxemic blood. Consequently, such injury is discussed to be reperfusion/hypoperfusion damage [9].

On the cellular status, HI actuates the activation of complex biochemical reactions, consisting of switching from oxidative to anaerobic metabolism, cellular energy failure, excitotoxicity, dysfunction of mitochondria, overload of intracellular calcium, production of free radicals, and inflammatory responses, which results in significant neuronal impairment and ultimately contributes to change in degrees of brain infarction, BBB (blood–brain barrier) dysfunction, and brain edema, finally resulting in irreversible brain injury.

The neurologic disorders extremely dwindle the quality of life in HIBD kids and escalate the socioeconomic burden on caregivers, families, and society. Currently, hypothermia is the only standard treatment for neonatal HIBD for full-term infants with moderate to severe HIE [10]. By this treatment, infants with the most severe type of HIE might not be saved, and this strategy involves the risk of severe disability or death, as nearly 50% of treated cases still die [11], and as many as 1/3 to 1/2 of sufferers demonstrate low Intelligence Quotient (IQ) at 6 to 7 years of age or constant neurologic abnormalities [12,13]. Therefore, more effective neuroprotective strategies are required. In this respect, several agents have been investigated to save the brain from irreversible damage or to postpone the pathological process, such as Erythropoietin, Melatonin, Metformin, stem cell therapy, etc., but only a few agents have been used in clinical studies [14]. Therefore, a search to explore better neuroprotective agents is under way.

In recent times, focus on plant research has increased globally and significant attention has been paid to medicinal plants due to their safety, cost-effectiveness, availability, long-term use, and limited side-effects. So far, the latest investigations have been looking at the potential of natural compounds isolated from plants, vegetables, fruits, and beverages to treat neurological disorders. Among them, the majority of naturally derived neuroprotective agents are polyphenolic compounds such as flavonoids which show protective effects in several animal models of experimental neurological disorders [15,16]. These naturally derived compounds have been reported as neuro-functional regulatory, anti-apoptotic, anti-inflammatory, and anti-oxidative agents [17–19]. In these topics, several plant extracts and plant-derived compounds, such as grape seed extract, resveratrol, and cannabinoi, have been scientifically identified to be useful in preventing or treating animal models of neonatal HIBD.

Although in previous review articles, natural products were studied as neuroprotective agents in various neurological and neurodegenerative diseases, none of them have focused on neonatal HIBD. In addition to introducing neonatal HI brain damage and its pathophysiology, in this study, we aimed to review the literature in scientific databases that investigate the protective effects of plant extracts or their constituents in experimental animal models of neonatal HI brain damage and their possible underlying mechanisms of action. For this purpose, articles indexed in PubMed, Science direct, and Scopus databases were evaluated, using the following keywords in English: (Neonatal [Title]) OR (Perinatal [Title]) OR (Neonate [Title]) OR (Newborn [Title]) AND (hypoxic-ischemic [Title]) OR
(hypoxia-ischemia [Title]) OR (hypoxic ischemic encephalopathy [Title]) AND (brain [Title]) AND (natural [Title/Abstract]) OR (plant [Title/Abstract]) OR (extract [Title/Abstract]) OR (herb [Title/Abstract]). In addition, the reference listing of the reclaimed essays and further resources comprising Google Scholar was screened.

2. Pathophysiology of Neonatal Hypoxic-Ischemic Brain Damage

2.1. Excitatory

In fact, HIE is caused by a restriction in blood supply (ischemia) and deprivation of adequate oxygen supply (hypoxia), which causes a switch to anaerobic metabolism. Anaerobic metabolism leads to depletion of adenosine triphosphate (ATP) and accumulation of lactic acid. This condition is known as primary energy failure, and occurs immediately after initial HI insult. At the cellular level, energy failure and ATP reduction results in failure of the cell membrane ion in pumping and consequently in flow of sodium and calcium ions accompanied by water flow into the cell. Following the process, the cytotoxic edema is eventuated due to the water flow which might lead to cellular swelling and cell lysis [9]. The following membrane depolarization unrolls voltage-sensitive calcium channels and leads to excessive calcium influx. Increase in intracellular Ca$^{2+}$ leads to production and release of excitatory amino acids, particularly glutamate. In the following stage, excess glutamate activates receptors such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors [20]. Activation of these receptors additionally promotes influx of Ca$^{2+}$ into the affected cells. Finally, the rise in intracellular Ca$^{2+}$ promotes production of reactive oxygen species (ROS), release of pro-radicals (such as free ions), and synthesis of excessive nitric oxide (NO) by neuronal NO synthase (nNOS), which is modulated by the NMDA receptors [20]. Furthermore, activation of lipases, proteases, and endonucleases are increased, which causes a release of fatty acids and membrane damage, and triggers a cascade reaction series which leads to cell death [20].

2.2. Free Radical Toxicity

Reoxygenation and reperfusion oxygen availability lead to the initial ischemic tissue and more ROS generation by mitochondria (via the electron transport chain) and damage integrity of membrane and organelle’s function. These activities lead to mitochondrial dysfunction which in turn can trigger ROS-induced ROS generation. Furthermore, hypoxanthine and pro-radicals such as iron cause large amounts of ROS formation. Mitochondrial impairment is one of the main factors involved in the apoptotic pathway of cell death. The second phase of injury is known as reperfusion injury and occurs hours later [20].

2.3. Inflammation

In addition to the described mechanisms, damaged neurons and activated endothelium produce various cytokines, including interleukins (IL-1, IL-6, IL-8, IL-10) and tumor necrosis factor (TNF)-α, which activate inflammatory response and trigger biochemical pathways that lead to secondary energy failure and a delay in neuronal cell death [20]. Secondary energy failure generally eventuates 6 to 48 h after initial HI insult and delays necrotic and apoptotic processes, that might continue up to days or weeks after birth [20]. Also, a delay in brain damage is associated with a decrease in production of neurotrophic growth factors, including epidermal growth factor (EGF), nerve growth factor (NGF), insulin-like growth factor (IGF), GDNF (glial cell-derived neurotrophic factor), BDNF (brain-derived neurotrophic factor), and VEGF (vascular endothelial growth factor), which apparently inhibit apoptosis and prompt cell proliferation and differentiation of the developing brain. On the other side, transcription factors comprising JNK (c-Jun N-terminal kinase) and NF-kB (nuclear factor kappa-beta) also demonstrate an important function in this point [20]. The damage progression proceeds and enters into the tertiary phase by progress in inflammation, alteration in neurogenesis, and impaired synaptogenesis and axonal growth [9].
2.4. Neuronal Death

Neuronal cell death induced by neonatal HI occurs either by necrosis or apoptosis. Necrotic cell death occurs immediately after the insult and is the prevailing pathway of cell death subsequent to irreversible or severe damage [9]. Apoptosis or programmed cell death planned apoptosis is a significant part of ultimate cell death. Apoptosis can last for days and even weeks after the initial insult. It was proposed that, in infants, apoptosis is possibly more critical in provoking cell death compared with necrosis [20].

3. Potential Mechanisms for Neuroprotective Strategies

As mentioned above, HIE consists of complex pathophysiologic mechanisms occurring in two energy failure stages. The first stage eventuates immediately after HI and the secondary stage eventuates 6–15 h after the initial insult. This delay offers a temporary therapeutic window for neuroprotective strategies, during which pharmacological interventions can be applied. To date, a broad range of propitious neuroprotective structures have been evaluated on experimental animal models of neonatal HIBD, but only a few agents have been used in clinical studies [14,21].

The pathophysiology of HIE enables multiple targets at different time points of the disease process. As an example, in the first stage, treatments are mostly concentrated on reduction of oxidative, apoptotic, and excitotoxic mediators of injury, whereas in the later stages, reduction of neurotrophic-evoked excitation features and inflammatory cytokines in the immature brain are targeted to contribute to regeneration of oligodendrocyte and neurons [22,23].

3.1. Reduction of Cellular Apoptosis and Oxidative Stress in HI

Apoptosis is categorized into two pathways, one is caspase-dependent and the second is caspase-independent, and both play an important task in the neonatal pathogenic process in HIBD. Therefore, apoptotic pathways are the main target for therapeutic interventions. Apaf-1, caspase, and Bcl-2 gene families demonstrate the major role in neuronal apoptosis determination. The Bcl-2 gene family includes pro-apoptotic (Bok, Bak, and Bax) and anti-apoptotic (Bcl-XL and Bcl-2) members that regulate cytochrome c translocation from mitochondria to cytoplasm, which is the initiator phase of the caspase-independent apoptosis. The mechanisms of release of pro-apoptotic Bcl-2 from the membrane of mitochondria might include the rupture of membrane of mitochondria, and anti-apoptotic members prevent this process. Caspases are intracellular proteases that function as initiators, and effectors of apoptosis function to activate other caspases’ cleavage [24]. Numerous agents have been evaluated to function on anti-apoptotic pathways, for example the proteins of Bcl-2 family become a prosperous object for drug targeting. Caspases are also one of the intriguing classes of proteins as a pharmacological target since caspase inhibitors are able to block apoptosis, for example, casp-3 inhibitors demonstrated neuroprotective activities in animal models of neonatal HIBD [25–27]. Furthermore, it has been recently demonstrated that autophagy (programmed cell death) reveals a significant efficacy in HIBD and neuroprotection, which can be obtained by regulating autophagy.

As discussed above, a large amount of free radical species, mainly ROS and RNS (reactive nitrogen species), comprising hydroxyl radical, superoxide, peroxynitrite, and hydrogen peroxide, accumulate rapidly in the brain after HI and cause oxidative stress that is able to initiate protein oxidation, lipid peroxidation, nucleic acid, and cell membrane damage, and eventually, lead to cell death. Due to the high level of polyunsaturated fatty acids, low concentration of endogenous antioxidant enzymes: SOD (superoxide dismutase), CAT (catalase), GPx (glutathione peroxidase), GST (glutathione S-transferase), GSH-Px (glutathione peroxidase), and high oxygen consumption, neonatal encephalon is more sensitive to oxidative damage than adults. Oxidative stress has a critical role in neuroinflammation and apoptosis, especially in neonatal HIBD. In addition, ROS are in charge of the numerous downstream factors which directly change the blood–brain barrier (BBB) integrity, and also effect the tight junction (TJ) proteins’ modification and the matrix metal-
Proteinases’ (MMPs) activation. Thus, the activation of MMPs with regards to oxidative stress is deemed as an inappropriate factor to segregate the integrity of the BBB. According to the evidence, it has been demonstrated that the changes in permeability of BBB and oxidative stress are generally involved in the neonatal pathogenesis of encephalon injury following HI insult. Many agents with anti-oxidative properties, including free radical scavengers (FRS) or free radical production inhibitors, such as melatonin or erythropoietin, have been reported to provide a protective effect in animal models of neonatal HIE \cite{28,29}. Furthermore, stabilization of the BBB after HIBD in neonates is a fundamental target in order to keep the microenvironment of cerebral homeostatic and the normal function of the neurons unchanged.

3.2. Reduction of Neurotrophic-Evoked Excitation and Inflammatory Cytokines in HI

Neuroinflammation subsequently occurs following HI, and anti-inflammatory treatments have been shown to heal brain injuries in neonates. For example, agents with anti-inflammatory effects such as allopurinol, deferoxamine, N-acetylcysteine, melatonin, and minocycline have demonstrated beneficial effects in animal models. Moreover, NF-kB inhibitors have also shown sustainable neuroprotection \cite{30–32}.

Supplementation of insufficient growth factors seems to be a promising therapeutic strategy, and administration of BDNF, IGF-1, and Erythropoietin ameliorate functional recovery and improve neurogenesis after neonatal HI injury. More recently, promoting neuronal regeneration with endogenous stem cells, such as mesenchymal progenitor/stem cells, has also been represented to promote functional outcomes in neonates \cite{33,34}.

3.3. Animal Model of HI

Animal models are normally the primary step in identifying mechanisms underlying illness and disease, to discover effective therapeutic treatments. Neonatal brain damage requires gestation for some months, and also the fetal and newborn maturation of the brain. Many animal models have reported information concerning the brain damage pathophysiology in term infants \cite{35}. A combination of proper animal models to direct these investigations will help us to comprehend human neonatal damage and the approach of therapeutic interventions. In this review, the bulk of the studies reviewed three kinds of animal models, mice, rat, and piglet, in HI. Neonatal HI mice studies were performed as outlined in the following procedure: At postnatal day 7, pups were anesthetized, and the left common carotid artery was subjected and Bovie cauterized. Subjecting to hypoxia was carried out in sealed chambers immersed in a water bath \cite{36}. In the rat model, usually, the neonatal rats (7 days old) were exposed to HIBD by the RiceVannucci modeling method. After anesthetizing rats, a longitudinal incision was made in the middle of their neck. The left common carotid artery was separated, and they were tightened by elastic bands. After the surgery, HI brain injury was induced in the piglets by total interruption of the carotid blood flow by tightening the elastic bands around the arteries \cite{38}.

4. Pharmacological Evidence of Natural Plant Products in Neonatal Hypoxic-Ischemic Brain Damage

4.1. Plant Extracts

4.1.1. Grape Seed Extract

Grape is one of the fruits that is a rich source of phenolic compounds and 60–70% of grape phenolic compounds are discovered in the seeds of the fruit. Grape seed extract (GSE) comprises several phenolic compounds, mainly procyanidins and proanthocyanidins monomers, polymers, and their gallate ester and resveratrol, which is the major compound that is extracted from the skin and seeds of grape \cite{39–41}. GSE is a powerful Free Radical Scavenger (FRS) of oxygen and has anti-lipid peroxidation activity \cite{32–45}.
GSE revealed anti-oxidant efficacy more than vitamins C and E [46]. GSE also displayed anti-inflammatory and anti-apoptotic actions [47–50]. In addition, GSE can reduce brain injury in forebrain ischemia in a gerbil model in adults [51].

Zheng and coworkers, in 2005, investigated the neuroprotective effect of GSE against neonatal HI brain injury [52]. In this study, rat pups at postnatal day 7 (P7) were subjected to HI insult and received GSE (50 mg/kg by intra peritoneal (i.p.)) 5 min before hypoxia and 4 h after reoxygenation (twice daily for 1 day). Brain weight loss was reduced from 20.0% in vehicle rats to 3.1% in treated rats, as well as improvement in the histopathologic brain score in hippocampus, thalamus, and cortex after GSE pretreatment. Additionally, lipid peroxidation markers 8-isoPGF$_{2\alpha}$ (8-isoprostaglandin F2α) and TBARS (thiobarbituric acid reactive substances) levels significantly reduced. In another study [53], GSE was injected at 5 min to 5 h after reoxygenation and it was found that GSE post-treatment reduces neurofunctional abnormalities and brain weight loss even when administered 3 h after injury. In addition, the reduction of lipid peroxidation marker 8-isoPGF$_{2\alpha}$ and pro-apoptotic protein c-jun in the rat brain cortex suggested that GSE exhibits neuroprotection through free radical inhibition and anti-apoptotic effects [53].

4.1.2. Grape Seed Proanthocyanidin Extract

Grape seed proanthocyanidin extract (GSPE) is a combination of biologically active flavanol compounds ranging from monomers such as gallic acid, epicatechin, catechins, and their gallate forms, to oligomeric proanthocyanidins. GSPE is known as one of the more potent natural antioxidants and its antioxidant capacity is significantly higher than vitamins E and C [54]. GSPE has been identified in various plants, for instance, cinnamon bark, pine bark, lotus, and apple, and also is widely distributed in red and white grape seeds. Many studies have reported a variety of pharmacological activities for GSPE including antioxidative [55,56], anti-inflammatory, anti-apoptosis [43], and anticancer properties. Recent studies have also been reported that suggest that GSPE possesses neuroprotective effects [56–58], for example against an adult rat model of ischemia-reperfusion injury [59].

Tu et al. demonstrated that GSPE significantly decreased brain infarct volume (approximately 50%) and improved neurobehavioral recovery in HIE mice models when pups were pretreated with GSPE (30 mg/kg, intraperitoneal (i.p.) injection) 20 min before HI [60]. In addition, the number of apoptotic cells and pro-apoptotic proteins’ expression (cleaved caspase-3 and bax) was significantly reduced, while expression of anti-apoptosis protein bcl-2 and the bcl2/bax ratio increased in the pretreated group, demonstrating the antiapoptotic role of GSPE [60].

4.1.3. Pomegranate Juice and Pomegranate Polyphenol Extract

The scientific name for pomegranate is *Punica granatum* Linn. Different parts of pomegranate (peel, seeds, and arils) are an important source of polyphenols, including tannins, mainly ellagitannins and gallotannins, flavonoids, mainly luteolin, quercetin, anthocyanidins, catechin, and epicatechin, alkaloids, etc. Moreover, pomegranate contains hydroxybenzoic acids such as gallic acid, ellagic acid, and ellagic acid glycosides [61–64]. Many studies have demonstrated that pomegranate has been linked with the prevention and treatment of a wide range of disorders, such as cardiovascular disease [65], hypertension [66], cancer (skin, breast, prostate, colon, lung, pancreatic) [67,68], arthritis [69,70], hyperlipidemia [71], obesity [72], diabetes [73], and wound healing activities [74]. The therapeutic potential of pomegranate fractions are correlated with its antioxidative [75–77], anti-inflammatory [78,79], anti-infective [80], anti-atherogenic, anti-hyperglycemic, immunomodulation [81,82], and anti-proliferative [83,84] properties. In recent decades, a number of in vivo and in vitro experimental researches have indicated the neuroprotective properties of pomegranate [85–87] against neurodegenerative diseases, particularly Alzheimer’s and depression-related models in several animal models [88–90]. In addition, other studies have demonstrated the effect of pomegranate and pomegranate seed extract on improvement of memory deficit in rat models of cerebral ischemia [91–93] and...
ischemia-induced anxiety in male rats [94]. In another study, pomegranate has been shown to improve cognitive and functional recovery after ischemic stroke [95].

In order to investigate the neuroprotective effect of pomegranate juice against neonatal HI brain insult, in 2005, Loren et al. [36] conducted a study on mature C57BL6 mice. In this study, pregnant mice received pomegranate juice in their drinking water at three dose levels (1:60, 1:80, and 1:320 dilutions of pomegranate juice concentrate). The treatment time for total groups was, in most cases, 15 days, which included 7 days in utero and 8 days ex utero for mice that sustained caspase-3 analysis, and 21 days, which included 7 days in utero and 14 days ex utero for mice that sustained histologic analysis. Seven-day-old neonatal mice were subjected to hypoxic-ischemic insult. They found significantly (>60%) decreased brain tissue loss as well as a decrease in activation of caspase-3 (84% in the hippocampus tissue and 64% in the cortex tissue) in the treated group as compared to control pups. The results demonstrated the effectiveness of pomegranate juice against neonatal HIBD through maternal dietary supplementation. The neuroprotective effects were observed. In a follow-up study, using the same neonatal HI mouse model, Loren et al. showed that maternal supplementation with pomegranate polyphenol extract (PPE) resulted in a significant decrease of HI-induced caspase-3 activation. The authors suggested that phenolic compounds of the juice are responsible for its neuroprotective effect [96]. Recent studies demonstrated that among polyphenol-containing foods, pomegranate juice had the highest concentration of measurable polyphenol due to the fact that the pomegranate juice antioxidant capacity was higher than green tea or red wine. Anthocyanins are the largest and most important group of flavonoids which exist in pomegranate juice [61,62,97,98].

4.1.4. Dendrobium officinale Extract

*Dendrobium officinale* (DO), that is used in traditional Chinese herbal medicine, represents various beneficial therapeutic activities, like chronic inflammation reduction. The neuroprotective activity of DO extract in ischemia-reperfusion-induced arrhythmia rat models has also been reported [99–101].

In 2019, Li found that DO extract (DOE) exerted neuroprotection against neonatal HIBD when 7-day-old rats were intra-gastrically administered different doses of DOE ((75–150–300) mg/kg/day, continuously for 14 consecutive days) after HI [37]. Results showed that after treatment with DOE, the levels of MDA (malondialdehyde), NO (nitric oxide), and NOS diminished and SOD activity increased in a dose-dependent manner, which indicated the enhancement of the antioxidant capacity in HIBD rats. In addition, the behavioral ability of rats significantly improved after DOE treatment in a dose-dependent manner. besides, DOE led to downregulation of Bax and caspase-3 and upregulation of Bcl-2 (demonstrating reduced neuronal apoptosis). Moreover, CI area percentage was remarkably diminished after treatment. They also examined the protein expression related to brain injury (KCC2 and HDAC1) and it was reported that after treatment with DOE, the expression of HDAC1 was diminished and KCC2 expression was elevated in the hippocampus and cortex. Meanwhile, determining the neurotrophic factors’ expression: HIF-1α (hypoxia-inducible factor 1- alpha), bFGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), and BDNF, after treatment with DOE, indicated that HIF-1α expression was remarkably diminished, and the bFGF, CNTF, and BDNF expression were enhanced. Altogether, this study demonstrated that the DOE is able to increase the neurotrophic factors’ expression and leads to neuronal apoptosis suppression and stimulates antioxidant capacity.

4.2. Phytochemicals

4.2.1. Verbascoside

Phenylethanoid glycosides are a kind of water-soluble natural phenolic compound that have exhibited neuroprotective activity [102]. Verbascoside (VB) (the chemical structure is shown in Figure 1a) is a typical phenylethanoid glycoside from lemon verbena [103]. VB is found in more than 150 types of plants [104]. There is numerous evidence that VB has
various biological activities, including antioxidant [105,106], anti-inflammatory [107–109], immunoregulatory [110], anticancer [111], and antimicrobial. In addition, several research studies have shown that VB also has neuroprotective properties against various neurological disorders in in vitro and in vivo experiments [112–114].

Figure 1. Chemical structures of the isolated compounds from plants in animal models of neonatal Hypoxic Ischemic brain injury. (a) Verbascoside, (b) Geniposide, (c) Hesperidin, (d) Quercetin, (e) Pterostilbene, (f) Vitexin, (g) Oxymatrine, (h) Coumestrol, (i) Plastoquinone, (j) Resveratrol, (k) Piceatannol, (l) Polydatin, (m) Vanillin, (n) Caffeine, (o) Crocin, (p) Tanshinone IIA, (q) Cannabidiol, (r) Huperzine A.

Wei et al. [115] investigated the neuroprotective effects of VB on a HIBD model in rat neonates. In this study, animals were subjected to HIBD at p7 and VB groups (60, 120, and 240 mg/kg) were administered through i.p. injection every 12 h after HI for two consecutive days. VB post-treatment (240 mg/kg) significantly reduced prolonged reflex latencies and brain infarct volume dose-dependently (120 and 240 mg/kg). The VB-treated group (240 mg/kg) also remarkably decreased the degree of degeneration, morphological damage, and necrosis in the cortex and hippocampus CA3 region compared with the HI group. Furthermore, autophagosome formation and the autophagy-related proteins’ expression (P62, Beclin-1, and LC3-II/I ratio) reduced after VB post-treatment.

4.2.2. Geniposide

Iridoid glycosides are phytochemicals that naturally occur in many plants [116,117]. Geniposide (Figure 1b) is one of the major iridoid glycoside compounds that are purified
from the Chinese herb *Gardenia jasminoides* [118]. Nearly 40 plants have been identified that contain geniposide [119]. Geniposide possesses diverse pharmacological activities, including anti-inflammatory [120,121], antidiabetic [122], anti-oxidative, and hepatoprotective [123]. In recent years, geniposide demonstrated excellent neuroprotective activities in experimental neurological dysfunctions, such as Parkinson’s disease [124], Alzheimer’s disease [125,126], and cerebral ischemia [127–129].

Liu et al., in 2019, studied the therapeutic effects and underlying mechanisms of geniposide against HI brain damage in neonatal mice. In this study, mice pups were subjected to HI insult at P10 and geniposide was administered (20 mg/kg) daily, intra-gastrically after HI. Findings showed that geniposide treatment significantly reduced the number of apoptotic neurons and also decreased the leakage of serum Immunoglobulin type G (IgG) into brain tissue. In addition, mRNA expression levels of pericyte markers, adherens, and tight junction proteins were upregulated after treatment, which meant that geniposide decreased the disruption of the BBB, which was induced by HI. Moreover, geniposide post-treatment attenuated astrogliosis and microgliosis. Microglia and astrocytes are two of the major neuroinflammation mediators [130]. To further elucidate the underlying molecular mechanism of geniposide-induced neuroprotection, it was found that Phosphoinositide 3-kinases/Protein kinase B (PI3K/Akt) expression signaling pathway-related protein was increased after treatment, which showed that geniposide probably exploits its neuroprotection activity via PI3K/Akt signaling pathway activation.

### 4.2.3. Hesperidin

Hesperidin (Figure 1c) belongs to the flavanone glycoside class of compounds, which was originally discovered in citrus fruits [131] but has been reported to occur in many plants other than citrus [132]. Several biological activities have been reported from Hesperidin, for example, antioxidative [133,134], anti-inflammatory [135], antitumor, and anti-allergenic properties. Hesperidin also has the ability to pass through the BBB [136]. In recent studies, both the in vivo and in vitro neuroprotective properties of hesperidin have been shown [137], which are attributed to its antioxidant and anti-inflammatory activities. This compound also had neuroprotective effects on amyloid β [138] against 3-nitropropionic acid-induced [139,140] and H₂O₂-induced [141] neurotoxicity. It also possesses antidepressant activities [142]. Another study reported that hesperidin enhances learning and memory in a rat model of cerebral ischemic-reperfusion injury [143].

Rong et al. demonstrated that hesperidin pretreatment in HIBD rat neonates increased the surviving brain volume from 49.8% to 72.9% and improved long-term behavioral development in oral administration of hesperidin (50 mg/kg/day) during 3 days in animals. Hesperidin pretreatment also markedly decreased Fluoro-Jade B stain-positive neurons in the cortex of the brain at post-HI [144]. In the culture media, pretreatment with hesperidin (1.6 µM) reduced the release of LDH (lactate dehydrogenase) and enhanced the levels of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), which indicated that hesperidin promotes neuronal survival. Moreover, levels of ROS and MDA decreased with hesperidin pretreatment in both in vivo and in vitro experimental models. Results also showed that hesperidin pretreatment suppressed FoxO3 phosphorylation, which indicated that possible molecular mechanisms of hesperidin neuroprotection are likely the result of activation of the PI3K/Akt survival signaling pathway and free radical reduction.

### 4.2.4. Quercetin

Quercetin (Que) is a flavonoid (3,3′,4′,5,6-Pentahydroxyflavone) (Figure 1d) which is distributed all over the world in fruits, vegetables, and many other dietary sources, including green tea, red wine, berries, and onions [145]. Quercetin is generally known as a strong antioxidant and free radical scavenger [146–148]. It also possesses anti-inflammatory and neuroprotective effects in brain injuries, such as traumatic [149] and ischemic/reperfusion [150]. Many recent studies have been conducted to examine the neuroprotective effects of quercetin on ischemic brain damage [151] in vitro [152,153] and
in various types of in vivo models, such as focal cerebral ischemia/reperfusion [154,155] and global cerebral ischemia [156]. Moreover, in some studies, delivery systems such as liposomal [157] and the nano-encapsulation approach have been used to deliver quercetin into the rat’s brain [158].

Qu, in 2014, conducted a study on postnatal 3-day-old rats and found that administration of Que (intra-gastrically once a day, 20 or 40 mg/kg from 2 h after HI to the day rats were sacrificed) significantly improved HI-induced myelin damage through strengthening survival of oligodendrocytes [159]. In 2019, Wu used a 7-day-old neonatal rat model of HIBD and administered Que (40 mg/kg/day) intra-gastrically once a day for 7 days. Results showed that Que treatment enhanced anti-apoptotic (Bcl-2) and reduced pro-apoptotic (Bax) proteins in cortical cells, as well as significantly attenuated the DNA-strand break induced by HI, which demonstrated the antiapoptotic effect of Que. Data also showed that Que treatment significantly decreased astrogliosis and microgliosis and downregulated the inflammatory factors’ expression (TNF-α, IL-1β, and IL-6) in rat cortex, which showed that Que had an anti-inflammatory effect and could protect brain cortex tissue from subsequent damage [160]. To study the mechanism of Que, authors examined the expressions of the TLR4/NF-κB signaling pathway. Based on the results, the phosphorylation of TLR4 (Toll-like receptor 4) reduced significantly and signals of p-p65 and p-p-IκBα were downregulated. These data confirmed that Que probably exerts its neuroprotection activity via suppression of the TLR4-mediated NF-κB pathway.

4.2.5. Pterostilbene

Pterostilbene (PTE) (3,5-dimethoxy-4-hydroxystilbene) (Figure 1e) is one of the resveratrol derivatives and was predominantly discovered in numerous varieties of grapes and blueberries [161,162]. PTE belongs to the phytoalexins family, and biosynthesizes in plants in response to biotic and abiotic stress [163]. The following evidence demonstrates that PTE possesses a protective effect against oxidative stress, inflammation, apoptosis, and shows anticancer and analgesic activities [164–166]. Recent studies suggest that pterostilbene also has neuroprotective effects in nervous system disorders such as lipopolysaccharide-induced learning and memory deficit [167], Alzheimer’s disease [168], anxiety [169], and ischemia-reperfusion brain damage [170,171].

In 2016, Li and coworkers reported that PTE (single dose—50 mg/kg) had neuroprotective effects against HI brain damage in rats when injected i.p. 30 min before insult. Brain infarct volume and brain edema markedly decreased (nearly 50%) and animals’ survival enhanced (from 78% to 95%). Additionally, PTE pretreatment significantly decreased neurological score and improved working memory impairment and motor deficit. Moreover, pro-inflammatory cytokines’ expression (IL-1, IL-6, and TNFα) and transcription factors (p-65 and NF-κβ) decreased in hippocampus CA1 and represented an anti-inflammatory effect of PTE. The results also showed inhibition of programmed cell death. Moreover, the level of TBARS and ROS were decreased and SOD activity was increased, which indicated the antiapoptotic and antioxidative role of PTE [172].

PTE pretreatment significantly prevented mRNA and protein expression of HO-1 (hemeoxygenase-1). On the other hand, HO-1 inhibitor, ZnP, can inhibit the neuroprotective effect of PTE. Authors suggested that HO-1 is a possible target of PTE in neuroprotection for oxidative, apoptotic, and inflammatory damage induced by HI [172].

4.2.6. Vitexin

Vitexin (5, 7, 4-trihydroxyflavone-8-glucoside) is an apigenin flavone glycoside (Figure 1f) that has been discovered in several plant species, including Vitex negundo seed [173], Passion flower [174], mimosa [175], wheat leaves [176], and hawthorn [177]. Earlier studies revealed that it possesses potent pharmacological actions such as antioxidant, anticancer [178], antiviral [179], anti-inflammatory [180], antihypertensive [181], and anti-depressant-like actions [182]. In addition, there are few reports on the neuroprotective efficacy of vitexin [183–185] such as its protective effect against cerebral I/R (is-
chemia/reperfusion) [186]. Vitexin is an HIF-1α inhibitor [187] and former researches have represented that the early suppression of HIF-1α after HI injury produced neuroprotection.

A study by Min et al. [188] revealed that administration of vitexin (single-dose: 30–60 mg/kg i.p.) at 5 min or 3 h after HI can significantly decrease brain infarct volume and improve long-term behavioral development as well as reduce neuronal cell death and brain tissue loss in neonatal rats dose-dependently. In addition, vitexin significantly inhibited upregulation of HIF-1α and VEGF protein levels. Vitexin also reduced the BBB disruption following brain edema. Throughout hypoxia, HIF-1α showed a significant function in VEGF expression. VEGF had a destructive effect on the surrounding vasculature that resulted in BBB disruption and subsequently, brain edema. Previous reports have shown that the VEGF expression inhibition throughout the primary cerebral ischemia stage or hypoxia led to the BBB protection. These data suggest that the primary HIF-1α inhibition along with vitexin decreased VEGF levels and led to protection of the BBB and brain edema reduction. Additionally, vitexin (45 mg/kg) was the most efficacious dose at 5 min after HI but lost its effects when administered 3 h after HI. These results indicated that the neuroprotection activity of vitexin is related to primary inhibition of HIF-1α and VEGF expression.

4.2.7. Oxymatrine

Oxymatrine (OMT) (Figure 1g) is one of the main alkaloids isolated from traditional Chinese herbal medicine *Sophora japonica* [189]. Oxymatrine has indicated anti-inflammatory [190,191], antiviral [192], antioxidant [193], anti-hepatic fibrosis [194], anti-apoptosis [195,196], and anticancer [197,198] effects. In recent years, in vitro [199] and in vivo investigations have represented that OMT possesses a neuroprotective effect against experimental brain injury models such as traumatic injury [200] and ischemia/reperfusion damage [201,202].

Liu et al., in 2015 [203], reported that OMT could ameliorate brain damage in HI rat neonates. In order to identify OMT’s specific effect on HI rat neonates and underlying mechanism, another in vivo and in vitro experimental study was designed on a model of neonatal HIBD [204]. In this study, 7-day-old rat pups were administered oxymatrine (120 mg/kg, i.p. injection) after HI every 12 h for 2 days. OMT treatment attenuated neuronal damage and necrotic cell loss and degeneration in cerebral hippocampus CA3 and cortex. In addition, the reflex latencies were reduced in treated pups.

The results of cultural hippocampal neurons obviously indicated that OMT improved cell viability, reduced LDH leakage, and attenuated intracellular Ca\(^{2+}\) and loss of MMP, and decreased the rate of cell apoptosis in neurons exposed to OGD/RP. In addition, OMT adjusted the expression of the mRNA and protein of the PI3K/Akt/GSK3β pathway, inhibited the expression of NR2B protein, and regulated apoptosis mediators (reduced caspase-3 and enhanced Bcl-2 and MCL-1 levels). These results demonstrated that OMT exerts neuroprotection against neonatal HIBD via regulating apoptosis, NR2B downregulation, and activation of the PI3K/Akt/GSK3β signaling pathway [203,204].

4.2.8. Coumestrol

Neuroprotective effects of estrogens against ischemic brain damage have been demonstrated previously [205]. Phytoestrogens are naturally occurring estrogen-like molecules found in many dietary plant sources and are structurally similar to estradiol [206–208]. Isoflavonoids are a subgroup of phytoestrogens with estrogen agonist ability and mimic estrogen’s neuroprotective properties [209,210]. Coumestrol (Figure 1h) is an isoflavonoid-like natural compound present in soybean, alfalfa, and red clover [211–213], and various studies have proven its anti-inflammatory [214], anti-adipogenesis [215], anti-aging [216], antioxidant, and anticancer [217–219] activities. In addition, the literature also indicates that coumestrol exerts neuroprotection against Alzheimer’s disease [220,221], multiple sclerosis, and brain global ischemia [222,223].
Recently, in one study, effects of coumestrol administration on neonatal HIBD have been investigated in male rats [224]. In this study, coumestrol (20 mg/kg) was injected i.p. immediately before HI, as a preventive, or 3 h post-hypoxia as a therapeutic intervention. Results showed that coumestrol pretreatment prevents HI-induced mitochondrial swelling. Furthermore, pre- and post-treatment with coumestrol protected the reference and the working memory from impairments as well as partially prevented late cognitive deficits in both the reference and working spatial memory tasks that were evaluated at P60. In addition, pre- or post-hypoxia treatment reduced tissue death in both ipsilateral brain hemisphere (20% recovery) and hippocampus (25% recovery). Finally, Coumestrol pre- and post-treatment attenuated late GFAP (glial fibrillary acidic protein, a marker of late HI-induced reactive astrogliosis) overexpression in the hippocampus and also demonstrated that this compound can provide long-term protective activity for astroglia against cell damage. Based on these data, the authors suggested that coumestrol neuroprotection mechanisms involve prevention of mitochondrial dysfunction and long-term cognitive deficits.

4.2.9. Plastoquinone

During the photosynthesis process, a large amount of ROS is generated in plants by the sunlight. So, chloroplasts are kept by a potent antioxidative system. Plastoquinone (Figure 1i) is an important component of the photosynthetic electron transport chains in chloroplasts and the reduced form of plastoquinone (plastoquinol) is a powerful antioxidant which diminishes generated ROS during photosynthetic reactions [225–228].

As mentioned above, HI causes mitochondrial dysfunction which actuates the pathological ROS production. Thus, antioxidants’ targeted delivery to the mitochondria is a productive therapeutic strategy to treat the detrimental impacts of HIBD. Previous data have indicated that SkQR1 (10-(6′-plastoquinonyl) decylrhodamine 19) (mitochondria-targeted antioxidant), which is a plastoquinone molecule linked to rhodamine derivative [229], has a protective effect on ROS-induced pathological conditions in a number of tissues, such as heart [230], kidney [231,232], eye [233], and brain [230–232,234,235]. SkQR1 also showed a neuroprotective effect in experimental models of brain trauma [232] and brain ischemia [236].

The neuroprotective effect of SkQR1 in neonatal HIBD was explored by Silachev et al. in 2019 [237]. They found that pretreatment with SkQR1 in neonatal HI rats at a dose of 2 µmol/kg (i.p. injection) markedly reduced infarct volume and diminished oxidative stress in the brain, as well as reduced nervous tissue loss. SkQR1 pretreatment also led to a significant decrease of long-term neurological deficits. Finally, SkQR1 improved short- and long-term behavioral deficiency as a consequence of HI-induced and remarkably enhanced sensorimotor performance. Administration of SkQR1 before or immediately after (10 min) HI exerts neuroprotection via diminishing brain deterioration and ameliorating long-term neurological tasks. It seems that the rationale of neuroprotective action of SkQR1 can reduce the ROS generation with mitochondrial origin.

4.2.10. Resveratrol

Resveratrol (3,5,4′-trans-trihydroxystilbene) (RES) is a natural phenolic compound with a stilbene structure (Figure 1j). Resveratrol is found naturally in various plant species; however, its dietary sources are limited. Some dietary sources of RES are peanuts, pistachio, berries, plums, pomegranates, grapes, and red wine (grapevines). Of all of these, grapes and red wine present the highest content [238–240]. RES has received extensive attention for its diverse pharmacological activities [241–246]. Besides, accumulating evidence indicated that RES treatment exerted neuroprotection against various brain disorders [247–249], including neurodegenerative diseases [250–252] such as Parkinson’s, Alzheimer’s, and Huntington’s diseases [253,254]. In addition, resveratrol also has neuroprotective effects in animal models of stroke [255], traumatic brain injury [256], and various kinds of ischemic brain injury ischemia [257,258] such as focal cerebral ischemia [259–261], global cerebral...
ischemia [262,263], and ischemia/reperfusion [264–267]. The RES mechanisms of action in neuroprotection might comprise antioxidation [268,269], anti-inflammation [270,271], and anti-apoptosis [272] effects.

Few reports have exhibited potential neuroprotective effects of RES in the pilot model of neonatal HI encephalopathy using both in vitro and in vivo approaches. West et al., in 2007, investigated the resveratrol effects on HI brain injury in both neonatal rats and mice [96]. In this study, the pups subjected to HI at postnatal day 7 and different concentrations of RES (20 mg/kg, 200 µg/kg, and 2 µg/kg) at several different points in time (24 h before hypoxia, 10 min before hypoxia, and 3 h after hypoxia) were administered via i.p. injection. Results indicated that RES at doses of 200 µg/kg or greater diminished caspase-3 and calpain activation at 24 h after the injury time dose-dependently, but only when its use before the injury showed both anti-apoptotic and necrotic cell death activity. RES also protected the brain from tissue loss 7 days after the injury. In addition to its protective effect in mouse neonates, RES also protects neonatal rats against HI, interestingly, when it is used after the injury. In another study in 2008, rat pups received RES (30 mg/kg) i.p. 30 min before or 30 min after HI. Results displayed an anti-apoptotic mechanism of RES via a remarkable decrease in expression level of Bax, the ratio of Bax/Bcl-2, and caspase-3, upon administration of RES at 30 min before HI but not when it was used 30 min after the injury [273]. Most of the surveys highlighted the short-term immunohistochemical and histological measurement of a set of biological markers and generally downgrade the long-term adverse effects and consequences of the treatment. In 2011, Karalis et al. investigated the delayed consequence of RES early administration through analysis of behavior and late neuropathological examination. Shortly, rats at P7 experienced HI and were treated instantly after hypoxia, receiving the 90 mg/kg of RES via i.p. injection. The remarkable difference was reported among the groups in righting water maze, rotarod, and reflex tests. According to the neuropathology study, a remarkable decrease in preservation of myelination and infarct eventuated after RES treatment. These results demonstrate that RES long-term neuroprotective activity on neonatal HI-induced damage on the gray and white tissue of the brain may be connected with the protection of behavioral functions [274].

Arteaga et al. conducted a study aiming to determine the RES activity as a preventive (before HI injury) or therapeutic agent (immediately after HI injury) on cellular and morphological damage and impairments in behavior in rat neonates. They found that pretreatment with RES reduced volume of infarction, preserved myelination, and minimized the astrogial reactive response. Moreover, long-term cognitive impairment significantly improved in adulthood. It was noticeable that none of these protective characteristics were found when RES was administered following HI [275]. All of these reported studies demonstrated the protective property of RES only when administered before HI (pre-treatment). However, Pan et al. reported that post-treatment with RES (100 mg/kg, i.p. injection three times at 0, 8, and 18 h respectively, after HI) remarkably decreased brain damage. They found that RES also decreased the expression of important inflammatory factors at the protein and mRNA levels, and at least partially through inhibition of microglia activation. However, RES demonstrated an anti-apoptotic activity, and changed the apoptosis-related genes’ expression, such as caspase3, Bax, and Bcl-2. These data indicate that inhibition of inflammation and apoptosis is a prosperous therapeutic strategy of RES post-treatment. The post-insult administration of RES has higher clinical relevance than pre-insult administration, though its specific molecular mechanism in the treatment of neuroinflammation is unclear [276]. Therefore, recently, Le and coworkers investigated the potential anti-inflammatory mechanism of RES on immature brains. They used the HIBI model in neonatal mice for in vivo and microglial cells for in vitro study. They found that RES significantly reduced the levels mRNA and protein, which were related to cytokines (TNF-α, IL-1β, and IL-6) in brain tissues following HI. As a result, RES remarkably ameliorated brain damage and neurobehavioral deficits by reducing neuroinflammatory responses. Additionally, RES reversed the reduction in the levels of SIRT1, like raising the levels of TLR4, MyD88, and NF-κB, whereas the administration of SIRT1-specific in-
hibitor prior to RES significantly reversed this effect, which demonstrated that RES exerted anti-inflammatory activity via inhibition of the TLR4/MyD88/NF-κB signaling pathway in vivo [277].

4.2.11. Piceatannol

Piceatannol (PIC) (Figure 1k) is a polyphenolic stilbene phytochemical that is found in large amounts in passion fruit seeds, berries, and grapes [278,279]. PIC is a hydroxylated analog of RES but has stronger free-radical-scavenging activity as well as greater bioavailability than RES [280,281]. Previous studies have reported that PIC has antioxidant, anti-inflammatory, and anticancer activity [282,283]. In addition, it exerts cardioprotective and neuroprotective properties [284–286].

Dumont et al. [287] recently showed that nutritional supplementation of pregnant and breastfeeding female rats with PIC (0.15 mg/kg/day via drinking water) could provide neuroprotection for HI neonates. In behavioral terms, maternal supplementation of PIC restored sensorimotor functions and recovered cognitive functions. Also, the number of pups with brain lesions, brain lesion size, and severity of edema inside brain lesions decreased in the treated group. Moreover, the spatial distribution of white matter fiber bundles significantly improved. These results were observed in pups as early as 3 h post-injury, which indicated the short-term effect of PIC. In addition, the hippocampal-dependent memory of pups was completely restored at P30, which indicated the long-term neuroprotective effect of maternal PIC consumption. The PIC-induced neuroprotection could be attributed to its antioxidant effect or modulation of the brain metabolism.

4.2.12. Polydatin

Polydatin (Figure 1l) is the main component of Polygonum cuspidatum (a traditional Chinese herb) but is also found in many daily diets, such as grape, peanut, hop cones, red wines, and chocolate. Polydatin is the glycoside of RES and the most abundant derivative of RES in nature [288]. Numerous studies have reported that polydatin has various pharmacological activities, comprising cardiovascular protection, anti-inflammation, antioxidation, anticancer, etc. [289]. Protective effects of polydatin against brain damage in animal models of ischemia-reperfusion have also been reported [290,291].

In one study by Sun et al., rat neonates were subjected to HIBI at P7 and polydatin (10 mg/kg) was administrated through i.p. injection once a day for 10 consecutive days. The results of a behavioral test showed that polydatin treatment led to enhancement of long-term learning and memory. In addition, BDNF expression was increased significantly in brains of treated pups. These results demonstrated that the protective effect of polydatin was possibly mediated via upregulation of BDNF, which showed that polydatin may have an important role in promoting neuronal survival and neuronal recovery following injury [292].

4.2.13. Vanillin

Vanillin (Figure 1m), the major component of vanilla orchids, is a natural aromatic compound. Vanillin is one of the best flavor ingredient in cosmetic, food, and drug products [293]. It has been reported that vanillin exhibits various pharmacological activities [294]. Recent reports revealed that vanillin could pass through the BBB and showed neuroprotective effects. For instance, vanillin reduced ischemia-induced neuronal damage in gerbils [295] or it showed a protective role against Parkinson’s disease [296].

In one study, the authors examined neuroprotective effects of Vanillin post-treatment on HIBD in rat neonates at postnatal day 7. Evaluation of brain damage revealed that vanillin (80 mg/kg, i.p. injection) significantly improved HI-induced neurobehavioral deficits and reduced brain infract volume as well as brain edema in a dose-dependent manner. In addition, neuronal degeneration and necrotic cell death were reduced in the hippocampal CA1 and CA3 and cortex regions in the brains of the treated group. Furthermore, vanillin post-treatment decreased IgG leakage into the brain tissue, reduced
the levels of MMPs, and upregulated the TJ-related proteins’ expression, which indicated that vanillin could improve BBB ultrastructure damage. Besides, endogenous antioxidant enzymes activities (SOD, GSH-Px, and CAT) and T-AOC (total antioxidant capacity) remarkably increased, and lipid peroxidation (reduction in the level of MDA content) was decreased. These results demonstrated that neuroprotection of vanillin might be attributed to its efficacy in oxidative stress inhibition and preserving BBB integrity, and reducing subsequent brain edema [297].

4.2.14. Caffeine

Caffeine (Figure 1n) belongs to methylxanthine alkaloid, which is found naturally in many plants. Coffee and tea are the main sources of caffeine. The main action of the methylxanthines is to stimulate the central nervous system. Caffeine is a non-selective adenosine antagonist and shows a wide range of actions on the brain [298,299]. Caffeine has been widely used to treat apnea of prematurity for the past 30 years as well as to facilitate the extubation in very low birth weight infants. It is available in the form of caffeine citrate and its active substance is caffeine base [300–302].

In one study by Back et al. [303], neonatal mice were subjected to hypoxia and administered caffeine. It was found that hypomyelination and ventriculomegaly were diminished by caffeine treatment. Results also led to a more normally arranged myelinated axon orientation in the caffeine-treated group. Additionally, the proportion of immature oligodendrocytes was enhanced. In order to determine the underlying mechanism of caffeine’s neuroprotective effect, in another study, rat pups were subjected to HI at postnatal day 7 and received caffeine citrate (20 mg/kg) immediately before and at 0, 24, 48, and 72 h after HI [304]. Results demonstrated that administration of caffeine citrate led to a significant decrease in the number of apoptotic cells in the parietal cortex and hippocampus of the treated rat’s brain, which showed that the antiapoptotic effect of caffeine was possibly responsible for its protective effects against neonatal HI brain injury.

4.2.15. Crocin

Crocus sativus L. stigma, generally known as saffron, is widely used to treat various diseases. Crocin (Figure 1o) is a water-soluble carotenoid and one of the main pharmacological active substances isolated from saffron. Previous studies have reported that crocin has high antioxidant capacity along with anti-inflammatory, anti-atherosclerotic, anticancer, and hypolipidemic effects [305]. Beside, neuroprotective properties of crocin have also been reported in experimental models of various brain disease, like cerebral ischemia-reperfusion [306,307], memory impairment [308], traumatic brain injury [309], and depression-related models [310].

Hypothermia therapy is one of the standard treatments for HIE in infants, although the efficacy is limited. Combination treatments are considered to increase the efficacy of hypothermia. Increasing the neuroprotective activity of hypothermia, combination treatments are deemed effective, and numerous therapeutic treatments have been examined as potential strategy in combination with hypothermia, comprising stem cells, erythropoietin, etc.

In one study [311], Huang and Jia investigated the protective effect of crocin and its combination with hypothermia against HIE in mouse neonates. Pups were subjected to HI at P7 followed by treatment with crocin (10 mg/kg) and hypothermia in combination. Levels of NO, ROS, and MDA were significantly reduced as well as mRNA expression of COX-2 (Cyclooxygenase-2) and iNOS (inducible nitric oxide synthase), which demonstrated the enhancement of the anti-oxidative effect of hypothermia after combined treatment. Furthermore, levels of IL-1β and TNF-α were markedly reduced, which indicated the enhancement of the anti-inflammatory effect of single hypothermia by combined treatment. Finally, combined treatment led to a significant reduction of neurological severity score, that showed the improvement of neurological function. These results demonstrated that crocin could increase the neuroprotective effect of hypothermia and can be used as a combined therapy with hypothermia.
4.2.16. Tanshinone IIA

Danshen, isolated from the *Salvia miltiorrhiza* Bunge, is a popular traditional Chinese herbal medicine which has been used for the treatment of cardiovascular and cerebrovascular disease. Tanshinone IIA (Tan IIA) (Figure 1q) is the most abundant pharmacologically active component of Danshen [312–314]. Tan IIA possesses anti-oxidative, anti-inflammatory, anti-apoptosis, antiplatelet aggregation, and anticancer activities [315–317], and exerts protective effects against cerebral I/R injury [318]. Tan IIA can be defined as an AchE (acetylcholinesterase) inhibitor that has the ability to penetrate the BBB [319].

Xia et al. found that the HIBI induced in the P7 neonatal rat model with administration of tanshinone IIA (i.p. injection at 10 mg/kg/d from 2 days before HI for 9 or 16 days) improved neuropathology and sensorimotor functions. Also, Tan IIA remarkably enhanced the antioxidant capacity in rat plasma and protected the C17.2 progenitor cells from AAPH-induced death. Furthermore, Tan IIA exhibited a protective activity on mitochondrial membrane potential [320].

4.2.17. Cannabidiol

Cannabinoids are a family of lipid mediators which modulate the synaptic transmission. Cannabinoids have emerged as promising neuroprotective agents in various brain disorders such as seizures, epilepsy, and Multiple Sclerosis (MS) [321–323]. In recent years, in vitro and in vivo investigations have reported that the cannabinoid receptor (CB1–CB2) agonist WIN55212–2 provided neuroprotection in animal models of neonatal HIE [324]. However, the production of psychoactive effects limits their therapeutic value. The phytocannabinoid, cannabidiol (CBD), is the major non-psychoactive component of *Cannabis sativa* plant (marijuana) [325]. CBD is well-known as a potent anti-inflammatory and antioxidant substance which shows neuroprotection in several neurodegenerative disorders using experimental animal models [326–328].

The neuroprotective effect of CBD against neonatal HIE was first demonstrated by Alvarez et al. [329]. It was reported that administration of CBD to newborn piglets at a dose of 0.1 mg/kg after HI insult leads to a reduction of brain edema and prevention of brain seizures. Also, CBD reduced cell loss and the number of degenerated neurons and showed additional cardio-protective effects. These effects can be attributed to a CBD-induced modulation of cerebral hemodynamic impairment and improvement of brain metabolic activity. Also, CBD did not show any significant side effects in treated piglets. Castillo et al. examined the effect of CBD (100 µM) in an in vitro model of neonatal HIE by exposing forebrain slices from newborn mice to oxygen-glucose deprivation [330]. The prevention of necrotic (reduction of LDH efflux to the medium) and apoptotic (reduction of caspase-9 concentration in tissue) cell death by CBD was observed. CBD also modulates inflammation (reduced IL-6 and TNF-α production and COX-2 expression) as well as excitotoxicity modulation (decreased glutamate release). Furthermore, iNOS expression was decreased. The results demonstrated that CB2 and adenosine—mainly A2A-receptors—participated in CBD-induced neuroprotection and led to activation of A2A, which was a principal mechanism of CBD neuroprotection. However, these reports demonstrated short-term neuroprotective activities of CBD in the immature brain after HI. In one study, Pazos et al. demonstrated long-term neuroprotective effects of CBD in newborn rats that received 1 mg/kg CBD after HI [331]. In this study, CBD reduced brain infarct volume and modulated brain excitotoxicity, inflammation, and oxidative stress 7 days following HI. It was reported that CBD provided long-lasting neuroprotection and treated animals’ neurobehavioral performance improved one month after HI. Also, they did not observe any noticeable side effects with CBD administration. In one study, Lafuente studied long-term (72 h after HI) effects of CBD. They found that post-HI i.v. injection of 0.1 mg/kg CBD in newborn piglets protects neurons, reduces cell death, and preserves astrocytes, which is related to its anti-inflammatory effect. Also, CBD improved neurobehavioral performance, brain activity, and stabilized metabolic activity [331]. In a follow-up study by Pazos et al. [332], they investigated the underlying mechanisms in in vivo CBD-induced
neuroprotection using the 1–2-day-old piglets treated with 1 mg/kg 30 min after HI. Findings indicated that CBD modulated excitotoxicity, inflammation, and oxidative stress, and both CB2 and 5HT1A receptors were involved in CBD-induced neuroprotection. In a recent study [333], the authors combined CBD with hypothermia in newborn piglets (receiving 30 min after the insult) and observed that the protective effect of combined therapy on excitotoxicity (glutamate/N-acetyl-aspartate ratio), inflammation (TNF-α), oxidative stress (oxidized protein levels), and on cell damage was greater than either hypothermia or CBD alone, which indicated that CBD and hypothermia act complementarily if used shortly following the insult. Similarly, Barata et al. [38] observed the additive neuroprotective effects for combining hypothermia and CBD in newborn pigs (received 1 mg/kg) in a longer follow-up study that resulted in more complete neuroprotection than CBD or hypothermia alone. According to the results, CBD can be applied as a promising and novel therapy for neonates with HIE.

4.2.18. Huperzine A

Huperzine A (HupA), a naturally occurring alkaloid which was firstly separated from the Chinese herb *Huperzia serrata*, is a potent AChE inhibitor [334]. It has been widely demonstrated that this agent represented learning- and memory-enhancing efficacy in animal and human studies. It also reversed or attenuated cognitive deficits in Alzheimer’s disease and other forms of dementia in animal experiments [335,336]. Besides, HupA also exerts multiple neuroprotective activities, for example it demonstrated neuroprotective properties, against hydrogen peroxide-, β-amyloid-, and glutamate-induced neurotoxicity and oxygen–glucose deprivation [337–339]. Furthermore, HupA has also been revealed to have neuroprotective activities against cerebral ischemic injury [340].

The protective activity of huperzine A against HIBD in neonatal rats was investigated by Wang et al. [341]. In this study, HI resulted in working memory impairments in pups after 5 weeks. Pups received huperzine A (0.1 mg/kg i.p.) once a day for 5 weeks after HI. They observed significant behavioral and histopathological protection against HI injury in rats treated with HupA. Furthermore, administration of HupA also decreased neuronal damage in ipsilateral hemisphere and provided remarkable protection in the hippocampal CA1 region. HupA showed its pharmacological activities by enhancing synaptic ACh levels via inhibition of AChE.

5. Conclusions

Despite the wide range of studies concerning neuroprotective drugs, currently, the only clinically relevant strategy to treat neonates with HI brain injury is hypothermia, but it is not able to reduce severe disabilities and is not completely successful, as approximately half of the affected neonates do not respond to it. Furthermore, hypothermia is expensive, and its therapeutic window is narrow. Thus, development of alternative and more effective therapeutic strategies is urgently needed.

The evidence presented in this review demonstrates the potential of natural plant products, especially polyphenols, in both prevention (agents administered before HI insult or through maternal consumption) and treatment (those administered after HI event) of neonatal HI brain damage, however regulated clinical trials have not been performed.

These compounds target both the early phase as well as later phase of injury via the following mechanisms: antioxidative, such as GSE, GSPE, and vanillin; anti-apoptosis, such as quercetin, oxymatrine, and caffeine; ameliorating blood barrier dysfunction, such as vanillin and vitexin; preventing microgliosis and inflammatory response, such as pterostilbene, etc. Moreover, some of these agents also regulate cell survival or cell death signaling pathways (Figure 2). For example, geniposide activates the PI3K/Akt cell survival signaling pathway or the neuroprotective effect of vitexin is related to early inhibition of HIF-1α. Many of these agents act not only on direct targets, but also on signaling pathways (see Table 1 and Figure 2). Since HIBD involves a series of complex progressive pathophysio-
logic processes, therefore, drugs acting on multiple targets or combinations of single target agents may be more effective in treating perinatal HIE.

When a HI event occurs, a substantial damage has taken place immediately after HI in the brain. Therefore, treatments have to start as early as possible in order to reduce further injury and promote regeneration. However, the preventive strategies will likely be the most effective therapeutic approaches. In this context, those compounds or extracts that act through maternal dietary supplementation, such as pomegranate juice and PIC, would be very interesting because nutritional approaches can easily be adopted as a preventive strategy in humans.

In conclusion, development of neuroprotective drugs from natural plant products is a prosperous approach for prevention and treatment of HI brain injury in neonates. Results of the presented studies may be useful for this purpose. In the future, more attention should be paid to further investigate the neuroprotective mechanisms, bioavailability, and metabolism of these agents, especially in humans.

Figure 2. The excitatory, free radical toxicity, inflammation, and neuronal cell death mechanism of plant extracts/plant-derived compounds in animal models of neonatal hypoxic-ischemic brain injury. (a) Verbascoside, (b) Quercetin, (c) Pterostilbene, (d) Vitexin, (e) Coumestrol, (f) Resveratrol, (g) Polydatin, (h) Vanillin, (i) Caffeine, (j) Crocin, (k) Tanshinone IIA, (l) Cannabidiol, (m) Pomegranate juice and Pomegranate polyphenol extract, (n) Grape seed extract and Grape seed proanthocyanidin extract, (o) Dendribium officinale.
Table 1. The studied plant extracts/plant-derived compounds in animal models of neonatal hypoxic-ischemic brain injury.

| Plant Extract/Compound | Administration Regimen | Dose | Species | Synergistic/Complementary Mechanism with/without Hypothermia | Effects/Molecular Mechanism | Reference |
|------------------------|-------------------------|------|---------|-------------------------------------------------------------|-----------------------------|-----------|
| Grape seed extract     | Pretreatment 5 min before HI, Post-treatment 4 h after reoxygenation | 50 mg/kg i.p. injection twice daily for 1 day | P7 neonatal rat pups | Reduction of brain weight loss; Improvement of histopathologic brain score; Antioxidant effect: Reduction of lipid peroxidation (reduced 8-iso-PGF2α and TBARS level); Post-treatment: No protection | | [52] |
| Grape seed extract     | Post-treatment 5 min to 5 h after reoxygenation | 50 mg/kg i.p. injection | P7 neonatal rat pups | Reduction of brain weight loss; Antioxidant effect: Reduction of lipid peroxidation (reduced 8-iso-PGF2α level); Anti-apoptotic effect: Reduction of pro-apoptotic protein c-jun | | [53] |
| Grape seed proanthocyanidin extract | Pretreatment 20 min before HI | 30 mg/kg i.p. injection | P7 neonatal mouse pups | Reduction of infarct volume; Improvement of neurobehavioral recovery; Anti-apoptotic effect: Reduction of apoptotic cells number; Reduction of pro-apoptotic proteins expression(bax and cleaved-caspase-3); Enhancement of anti-apoptotic (bcl-2) proteins expression and increased ratio of bcl2-to-bax | | [60] |
| Pomegranate juice      | Maternal dietary supplementation 1:60 or 1:80 or 1:320 dilutions of pj concentrate, during last third of pregnancy and litter suckling | | P7 neonatal mouse pups | Reduction of brain tissue loss; Anti-apoptotic effect: Reduction of caspase-3 activation | | [36] |
| Pomegranate polyphenol extract | Maternal dietary supplementation 4.8 mg/day during pregnancy and litter suckling | | P7 neonatal mouse pups | Anti-apoptotic effect; Reduction of caspase-3 activation | | [96] |
| Dendrobium officinale extract | Post-treatment (75 or 150 or 300) mg/kg, intra gastric administration, Daily for 14 consecutive days | | P7 neonatal rat pups | Improvement of behavioral ability; Reduction of CI area percentage; Regulation of brain injury-related proteins’ expression (diminished HDAC1 and elevated KCC2 expression); Antioxidant effect: Diminished levels of NOS, NO, and MDA; Enhancement of antioxidant capacity (increased SOD activity); Anti-apoptotic effect: Downregulated caspase-3 and Bax expression; Upregulated Bcl-2 expression; Anti-inflammatory effect: Regulation of neurotrophic factors expression (increased expression of BDNF, bFGF, and CNTF); Mechanism: Inhibition of HIF-1α | | [37] |
| Plant Extract/Compound | Administration Regimen | Dose | Species | Synergistic/Complementary Mechanism with/without Hypothermia | Effects/Molecular Mechanism | Reference |
|------------------------|------------------------|------|---------|-------------------------------------------------------------|-----------------------------|-----------|
| Caffeine               | Pretreatment immediately before HI, post-treatment 0, 24, 48, and 72 h after HI | 20 mg/kg | P7 neonatal rat pups | Decreased ventriculomegaly and hypomyelination More normally arranged myelinated axon orientation Enhanced proportion of immature oligodendrocytes Anti-apoptotic effect Decreased number of apoptotic cells | | [303] |
| Pterostilbene         | Pretreatment 30 min before HI | 50 mg/kg i.p. injection | P7 neonatal rat pups | Enhancement of animal survival Reduction of neurological score Improvement in motor coordination, motor deficit, and working memory deficit Reduction of brain infarct volume Reduction of brain edema Anti-inflammatory; (decreased TNF-α, IL-1, and IL-6 expression; decreased p-65 and NF-κβ expression) Antioxidant: (decreased TBARS and ROS level; increased SOD activity) Antiapoptotic: (inhibition of programmed cell death) Mechanism: HO-1 signaling pathway (Prevention of HO-1 mRNA and protein expression) | | [172] |
| Quercetin             | Pretreatment 40 mg/kg/day Intra-gastrically injection once a day for 7 days, last administration was 2 h after HI | | P7 neonatal rat pups | Anti-apoptosis: (downregulated Bax, upregulated Bcl-2, attenuated DNA-strands breaks) Anti-inflammatory: (attenuated astrogliosis and microgliosis; downregulated IL-6, IL-1β, and TNF-α) Mechanism: Suppression of TLR4-mediated NF-κB signaling pathway (decreased TLR4 phosphorylation and downstream signals of p65 and p-IκBα) | | [159] |
| Resveratrol           | Pretreatment 24 h/10 min before HI Post-treatment 3 h after HI | 20 mg/kg or 200 µg/kg or 2 µg/kg i.p. injection | P7 Neonatal rat and mouse pups | Pretreatment: Protecting brain from tissue loss Preventing apoptosis and necrosis (diminished caspase-3 and calpain activation) Post-treatment: No protection | | [96] |
|                         | Post-treatment 30 min before HI Post-treatment 30 min after HI | 30 mg/kg i.p. injection | P7 neonatal rat pups | Anti-apoptotic: (reduced expression level of Bax, caspase-3, and the ratio of Bax/Bcl-2) Post-treatment Not protection | | [273] |
|                         | Post-treatment Immediately after HI | 90 mg/kg i.p. injection | P7 neonatal rat pups | Reduced infarct volume Preserved myelination Behavioral tests (P6–P66): Improved early reflexes and sensorimotor functions Improved learning/memory function | | [274] |
| Plant Extract/Compound | Administration Regimen | Dose | Species | Synergistic/Complementary Mechanism with/without Hypothermia | Effects/Molecular Mechanism | Reference |
|------------------------|------------------------|------|---------|------------------------------------------------------------|-----------------------------|-----------|
|                        | Pretreatment           |      |         |                                                            |                             |           |
|                        | 10 min before HI       | 20 mg/kg i.p. injection | P7 neonatal rat pups | Pretreatment: Reduced infarct volume | Anti-inflammation: (reduction of inflammatory factors expression; inhibition of microglia activation) | [275]     |
|                        | 10 min before HI       | 100 mg/kg i.p. injection | P7 neonatal rat pups | Preserved myelination | Anti-apoptosis: (regulation of Bax, Bcl-2 and caspase3 expression) | [276]     |
|                        | Immediately after HI   | 100 mg/mL i.p. injection | P7 neonatal mouse pups | Minimized astroglial reactive response | Anti-inflammation: (reduction of expression levels of IL-1β, IL-6, and TNF-α) | [277]     |
|                        |                        |      |         |                                                            | Enhancement of SIRT1 level |           |
|                        |                        |      |         |                                                            | Inhibition of TLR4/MyD88/NF-κB signaling pathway (reduced TLR4, MyD88, NF-κB levels) |           |
| Tanshinone IIA         | From 2 days before HI for 9 or 16 days | 10 mg/kg/day i.p. injection | P7 neonatal rat pups | Improved neuropathology and sensorimotor functions | Improved neurobehavioral deficits | [320]     |
|                        |                       |      |         |                                                            | Improved antioxidant capacity |           |
|                        |                       |      |         |                                                            | Protect mitochondrial membrane potential |           |
| Vanillin               | Post-treatment         | 80 mg/kg i.p. injection | P7 neonatal rat pups | Improved neurobehavioral deficits | Reduced brain infarct volume | [297]     |
|                        | Immediately after HI   |      |         |                                                            | Reduced brain edema |           |
|                        |                        |      |         |                                                            | Reduced neuronal degeneration and necrotic cell death |           |
|                        |                        |      |         |                                                            | Preserving BBB integrity (decreased IgG leakage, reduced levels of MMPs, upregulated expression of TJ-related proteins) |           |
|                        |                        |      |         |                                                            | Inhibiting oxidative stress (increased SOD, GSH-Px, and CAT; increased T-AOC; decreased lipid peroxidation (MDA content)) |           |
| Verbascoside           | Post-treatment         | (60 or 120 or 240) mg/kg, i.p. injection, every 12 h for two consecutive days | P7 neonatal rat pups | Reduction of prolonged reflex latencies | Reduction of degeneration and morphological damage of neurons | [115]     |
|                        |                        |      |         |                                                            | Reduction of autophagosome formation |           |
|                        |                        |      |         |                                                            | Reverse expression level of autophagy-related proteins (Beclin-1, LC3-II/I ratio, and P62) |           |
| Plant Extract/Compound | Administration Regimen | Dose | Species | Synergistic/Complementary Mechanism with/without Hypothermia | Effects/Molecular Mechanism | Reference |
|-----------------------|------------------------|------|---------|-----------------------------------------------------------|----------------------------|-----------|
| Vitexin               | Post-treatment          |      |         |                                                           | 5 min after HI: Reduction of brain infarct volume | [188]     |
|                       | 5 min or 3 h after HI  | (30 or 45 or 60) mg/kg | P7 neonatal rat pups | Improvement of long-term behavioral development | Reduction of brain edema |          |
|                       | i.p. injection         | single dose                 | | Attenuation of neuronal cell death and brain tissue loss | |          |
|                       |                        |                              | | Attenuation of BBB disruption: (reduction of IgG staining and brain water content) | |          |
|                       |                        |                              | | Mechanism: inhibition of HIF-1α/VEGF (decreased HIF-1α and VEGF protein levels) | |          |
|                       |                        |                              | | 3 h after HI: vitexin lost its neuroprotection | |          |
| Cannabidiol           | Post-treatment         | 0.1 mg/kg | P3–P5 newborn piglets | Prevention of necrotic cell death (reduced LDH efflux to the medium) | Cardio-protective effects | [329]     |
|                       | 15 and 240 min after HI | i.v. injection | | Anti-apoptotic: (reduced caspase-9 level) | |          |
|                       |                        |                              | | Anti-inflammatory: (reduced IL-6 and TNF-α level; reduced COX-2 expression level) | |          |
|                       |                        |                              | | Excitotoxicity modulation: (decreased glutamate release) | |          |
|                       |                        |                              | | Anti-inflammatory: (decreased iNOS expression) | |          |
|                       |                        |                              | | Mechanism: Activation of A2A and CBD receptors | |          |
|                       | Post-treatment         | 100 µM | Forebrain slices from P7–P10 neonatal mouse pups | Long follow-up study (72 h after HI): | | [330]     |
|                       |                        |                              | | Improved neurobehavioral performance | |          |
|                       |                        |                              | | Improved brain activity | |          |
|                       |                        |                              | | Stabilized metabolic activity | |          |
|                       |                        |                              | | Reduced cell death | |          |
|                       |                        |                              | | Anti-inflammatory effect (protects astrocytes) | |          |
|                       | Post-treatment         | 0.1 mg/kg | P1–P3 newborn piglets | Long follow-up study (7 days or one month after HI): | | [331]     |
|                       | 15 and 240 min after HI | i.v. injection | | Reduced infarct volume | |          |
|                       |                        |                              | | Modulated brain excitotoxicity, oxidative stress, and inflammation 7 days after HI | |          |
|                       |                        |                              | | Improved neurobehavioral performance one month after HI | |          |
|                       | Post-treatment         | 1 mg/kg | P7–P10 neonatal rat pups | | | [332]     |
|                       | 10 min after HI        | i.v. injection | | | |          |
|                       | Post-treatment         | 1 mg/kg | P1–P2 newborn piglets | Modulation of excitotoxicity, oxidative stress and inflammation | | [333]     |
|                       | 30 min after HI        | i.v. injection | | Mechanism: Involvement of CB2 and SHT1A receptors | |          |
|                       | Combined with hypothermia |                              | | | |          |
|                       | Post-treatment         | 1 mg/kg | P1–P2 newborn piglets | Short follow-up study: | | [38]      |
|                       | 30 min after HT        | i.v. injection | | Modulation of excitotoxicity, inflammation, oxidative stress, and cell damage was greater than either hypothermia or CBD alone | |          |
|                       | Combined with hypothermia | | | | |          |
|                       | Cannabidiol treatments reduced the oxidized protein and TNFα levels | | | | |          |
| Plant Extract/Compound | Administration Regimen | Dose | Species | Synergistic/Complementary Mechanism with/without Hypothermia | Effects/Molecular Mechanism | Reference |
|------------------------|-------------------------|------|---------|------------------------------------------------------------|-----------------------------|-----------|
| Coumestrol             | Pretreatment Immediately pre-hypoxia | 20 mg/kg i.p. injection | P7 male neonatal rat pups | Reverse the induction of increases in lactate/N-acetyl-aspartate, glutamate/N-acetyl-aspartate, TNFα, or apoptosis Modulate the brain excitotoxicity and inflammation More complete neuroprotection than CBD or hypothermia alone | Long follow-up study: Improved brain activity Decreased microglial activation | [334] |
| Crocin                 | Post-treatment Immediately or 2 h after HI | 10 mg/kg combined with hypothermia | P7 neonatal mouse pups | Reduced neurological severity score Anti-oxidative effect: (reduced levels of MDA, ROS, and NO; reduced mRNA expression of iNOS and COX-2) Anti-inflammatory effect: (reduced IL-1β and TNF-α levels) | | [311] |
Author Contributions: Conceptualization, M.H.F., M.P. and A.P.; methodology, H.M.; investigation, H.M. and A.B.; writing—original draft preparation, H.M. and A.B.; writing—review and editing, P.M., M.H.F., M.P. and A.P.; supervision, M.H.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AChE: acetylcholinesterase; Akt: protein kinase B; AMPA: N-methyl-d-aspartate; ATP: adenosine triphosphate; BBB: blood-brain barrier; BDNF: Brain-derived neurotrophic factor; bFGF: basic fibroblast growth factor; i.p.: intraperitoneal; CAT: Catalase; CB1: cannabinoid receptor; CBD: Cannabidiol; CNTF: Ciliary neurotrophic factor; COX-2: Cyclooxygenase-2; DOE: Dendrobium officinale extract; EGF: epidermal growth factor; GDNF: Glial cell-derived neurotrophic factor; GFAP: Glial fibrillary acidic protein; GPx: Glutathione peroxidase; GSE: grape seed extract; GSH-Px: Glutathione peroxidase; GSPE: grape seed proanthocyanidin extract; HI: hypoxia-ischemia; HIBD: hypoxic-ischemic brain damage; HIE: hypoxic-ischemic encephalopathy; HIF-1α: Hypoxia-inducible factor 1-alpha; HO-1: Heme oxygenase-1; HupA: Huperzine A; IGF: insulin-like growth factor; IgG: Immunoglobulin G; IL: interleukin; iNOS: inducible nitric oxide synthase; I/R: ischemia/reperfusion; IQ: intelligence quotient; 8-isoPGF2α: 8-isoprostaglandinF2α; JNK: c-Jun N-terminal kinase; LDH: Lactate dehydrogenase; MDA: Malondialdehyde; MMPs: matrix metalloproteinases; MS: Multiple sclerosis; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; NF-κβ: nuclear factor kappa-beta; NGF: nerve growth factor; NMDA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NO: nitric oxide; nNOS: neuronal nitric oxide synthase; OMT: Oxymatrine; P7: postnatal day 7; PI3K: phosphatidylinositol 3-kinase; PGE2: prostaglandin E2; PPE: pomegranate polyphenol extract; PTE: Pterostilbene; Que: Quercetin; RNS: reactive nitrogen species; RES: Resveratrol; ROS: reactive oxygen species; SIRT1; SkQR1: 10-(6′-plastoquinonyl) decylrhodamine 19; SOD: Superoxide dismutase; Tan IIA: Tanshinone IIA; T-AOC: total antioxidant capacity; TBARS: Thiobarbituric acid reactive substances; TJ: tight junction; TLR4: Toll-like receptor 4; TNF: tumor necrosis factor; VB: Verbascoside; VEGF: Vascular endothelial growth factor.

References

1. Kruszewski, S.P. Neonatal Brain Injury. *N. Engl. J. Med.* 2005, 352, 1985–1995. [CrossRef]
2. Lawn, J.E.; Cousens, S.; Zupan, J. 4 Million Neonatal Deaths: When? Where? Why? *Lancet* 2005, 365, 891–900. [CrossRef]
3. Dilenge, M.E.; Majnemer, A.; Shevell, M.I. Long-Term Developmental Outcome of Asphyxiated Term Neonates. *J. Child Neurol.* 2001, 16, 781–792. [CrossRef]
4. Graham, E.M.; Ruis, K.A.; Hartman, A.L.; Northington, F.J.; Fox, H.E. A Systematic Review of the Role of Intrapartum Hypoxia-Ischemia in the Causation of Neonatal Encephalopathy. *Am. J. Obstet. Gynecol.* 2008, 199, 587–595. [CrossRef] [PubMed]
5. Kurinczuk, J.J.; White-Koning, M.; Badawi, N. Epidemiology of Neonatal Encephalopathy and Hypoxic-Ischaemic Encephalopathy. *Early Hum. Dev.* 2010, 86, 329–338. [CrossRef] [PubMed]
6. Airede, A.I. Birth Asphyxia and Hypoxic-Ischaemic Encephalopathy: Incidence and Severity. *Ann. Trop. Paediatri.* 1991, 11, 321–335. [CrossRef] [PubMed]
7. De Haan, M.; Wyatt, J.S.; Roth, S.; Varga-Khadem, F.; Gadian, D.; Mishkin, M. Brain and Cognitive-Behavioural Development after Asphyxia at Term Birth. *Dev. Sci.* 2006, 9, 350–358. [CrossRef]
8. Roth, S.C.; Edwards, A.D.; Cady, E.B.; Delpy, D.T.; Wyatt, J.S.; Azzopardi, D.; Baudin, J.; Townsend, J.; Stewart, A.L.; Reynolds, E.O. Relation between cerebral oxidative metabolism following birth asphyxia, and neurodevelopmental outcome and brain growth at one year. *Dev. Med. Child Neurol.* 1992, 34, 285–295. [CrossRef]
9. Gluckman, P.D.; Pinal, C.S.; Gurr, A.J. Hypoxic-Ischemic Brain Injury in the Newborn: Pathophysiology and Potential Strategies for Intervention. *Semin. Neonatol.* 2001, 6, 109–120. [CrossRef]
10. Bunney, P.E.; Zink, A.N.; Holm, A.A.; Billington, C.J.; Kots, C.M. Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet. *Physiol. Behav.* 2017, 176, 139–148. [CrossRef]
11. Gluckman, P.D.; Wyatt, J.S.; Azzopardi, D.; Ballard, R.; Edwards, A.D.; Ferriero, D.M.; Polin, R.A.; Robertson, C.M.; Thoresen, M.; Whitelaw, A.; et al. Selective Head Cooling with Mild Systemic Hypothermia after Neonatal Encephalopathy: Multicentre Randomised Trial. *Lancet* 2005, 365, 663–670. [CrossRef]

12. Azzopardi, D.; Strohm, B.; Marlow, N.; Brocklehurst, P.; Deierl, A.; Eddam, O.; Goodwin, J.; Halliday, H.L.; Juszczak, E.; Kapellou, O.; et al. Effects of Hypothermia for Perinatal Asphyxia on Childhood Outcomes. *N. Engl. J. Med.* 2014, 371, 140–149. [CrossRef] [PubMed]

13. Shankaran, S.; Pappas, A.; McDonald, S.A.; Vohr, B.R.; Hintz, S.R.; Yolton, K.; Gustafson, K.E.; Leach, T.M.; Green, C.; Bara, R.; et al. Childhood outcomes for hypothermia for perinatal encephalopathy. *Obstet. Gynecol. Surv.* 2012, 67, 617–619. [CrossRef]

14. Ournal, T.H.E.J.; Ediatrics, O.F.P. Neuroprotective Strategies in Neonatal Brain Injury. *J. Pediatr.* 2017, 192, 22–32. [CrossRef]

15. Simonyi, A.; Wang, Q.; Miller, R.L.; Yusof, M.; Shelat, P.B.; Sun, A.Y.; Sun, G.Y. Polyphenols in Cerebral Ischemia: Novel Targets for Neuroprotection. *Mol. Neurobiol.* 2005, 31, 135–147. [CrossRef]

16. Ahmad, N.; Khan, Z.; Hasan, N.; Basit, A.; Zohranea, S. Neuroprotective Agents, Natural Plant Herbs & Drugs in Ischemic Stroke: A Review. *PharmaTutor* 2017, 5, 29–36.

17. Costa, S.L.; Silva, V.D.A.; dos Santos Souza, C.; Santos, C.C.; Paris, I.; Muñoz, P.; Segura-Aguilar, J. Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases. *Neurotox. Res.* 2016. [CrossRef]

18. Su, S.; Hsieh, C. Anti-Inflammatory Effects of Chinese Medicinal Herbs on Cerebral Ischemia. *Chin. Med.* 2011, 6, 1–9. [CrossRef]

19. Pohl, F.; Kong, P.; Lin, T. The Potential Use of Plant Natural Products and Plant Extracts with Antioxidant Properties for the Prevention/Treatment of Neurodegenerative Diseases: In Vitro, In Vivo and Clinical Trials. *Molecules* 2018, 23, 3283. [CrossRef]

20. Albrecht, M.; Zitta, K.; Groenendaal, F.; Van Bel, F.; Deierl, A.; Goodwin, J.; Halliday, H.L.; Juszczak, E.; Kapellou, O.; et al. Effects of Hypothermia for Perinatal Asphyxia on Childhood Outcomes. *N. Engl. J. Med.* 2014, 371, 140–149. [CrossRef] [PubMed]

21. Nair, J.; Kumar, V.H.S. Current and Emerging Therapies in the Management of Hypoxic Ischemic Encephalopathy in Neonates. *Children* 2018, 5, 99. [CrossRef] [PubMed]

22. Wu, Q.; Chen, W.; Sinha, B.; Tu, Y.; Manning, S.; Thomas, N.; Zhou, S.; Jiang, H.; Ma, H.; Kroessler, D.A.; et al. Neuroprotective Agents for Neonatal Hypoxic-Ischemic Brain Injury. *Drug Discov. Today* 2015, 20, 1372–1381. [CrossRef] [PubMed]

23. Dixon, B.J.; Reis, C.; Ho, W.M.; Tang, J.; Zhang, J.H. Neuroprotective strategies after neonatal hypoxic ischemic encephalopathy. *Int. J. Mol. Sci.* 2015, 16, 22368–22401. [CrossRef]

24. Grow, J.; Barks, J.D.E. Pathogenesis of Hypoxic-Ischemic Cerebral Injury in the Term Infant: Current Concepts. *Clin. Perinatol.* 2002, 29, 585–602. [CrossRef]

25. Northrington, F.J.; Graham, E.M.; Martin, L.J. Apoptosis in perinatal hypoxic-ischemic brain injury: How important is it and should it be inhibited? *Brain Res. Rev.* 2005, 50, 244–257. [CrossRef]

26. Yin, W.; Cao, G.; Johnnides, M.J.; Signore, A.P.; Luo, Y.; Hickey, R.W.; Chen, J. TAT-Mediated Delivery of Bcl-XL Protein Is Neuroprotective against Neonatal Hypoxic-Ischemic Brain Injury via Inhibition of Caspases and AIF. *Neurobiol. Dis.* 2006, 21, 358–371. [CrossRef]

27. Han, B.H.; Xu, D.; Choi, J.; Han, Y.; Xanthoudakis, S.; Roy, S.; Tam, J.; Vaillancourt, J.; Colucci, J.; Siman, R.; et al. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. *J. Biol. Chem.* 2002, 277, 30128–30136. [CrossRef]

28. Alonso-Alconada, D.; Álvarez, A.; Arteaga, O.; Martínez-Ibargüen, A.; Hilario, E. Neuroprotective Effect of Melatonin: A Novel Therapy against Perinatal Hypoxia-Ischemia. *Int. J. Mol. Sci.* 2013, 14, 9379–9395. [CrossRef]

29. Arteaga, O.; Álvarez, A.; Revuelta, M.; Santaoalla, F.; Urtasun, A.; Hilario, E. Role of Antioxidants in Neonatal Hypoxic–Ischemic Brain Injury: New Therapeutic Approaches. *Int. J. Mol. Sci.* 2017, 18, 265. [CrossRef]

30. Shen, H.; Hu, X.; Liu, C.; Wang, S.; Zhang, W.; Gao, H.; Stetler, R.A.; Gao, Y.; Chen, J. Ethyl Pyruvate Protects against Hypoxic-Ischemic Brain Injury via Anti-Cell Death and Anti-Inflammatory Mechanisms. *Neurobiol. Dis.* 2010, 37, 711–722. [CrossRef]

31. Yang, D.; Sun, Y.Y.; Lin, X.; Baumann, J.M.; Dunn, R.S.; Lindquist, D.M.; Kuan, C.Y. Intranasal Delivery of Cell-Penetrating Anti-NF-κB Peptides (Tat-NBD) Alleviates Infection-Sensitized Hypoxic-Ischemic Brain Injury. *Exp. Neurol.* 2013, 247, 447–455. [CrossRef]

32. Yildiz, E.P.; Ekici, B.; Tath, B. Neonatal Hypoxic Ischemic Encephalopathy: An Update on Disease Pathogenesis and Treatment. *Expert Rev. Neurother.* 2017, 17, 449–459. [CrossRef] [PubMed]

33. Donega, V.; van Velthoven, C.T.; Nijboer, C.H.; Kavelaars, A.; Heijnen, C.J. The endogenous regenerative capacity of the damaged newborn brain: Boosting neurogenesis with mesenchymal stem cell treatment. *J. Cereb. Blood Flow Metab.* 2013, 33, 625–634. [CrossRef] [PubMed]

34. Chen, A.I.; Xiong, L.-J.; Tong, Y.U.; Mao, M. The Neuroprotective Roles of BDNF in Hypoxic Ischemic Brain Injury. *Biomed. Rep.* 2013, 1, 167–176. [CrossRef]

35. Yager, J.Y.; Ashwal, S. Animal models of perinatal hypoxic-ischemic brain damage. *Pediatr. Neurol.* 2009, 40, 156–167. [CrossRef]

36. Loren, D.J.; Seeram, N.P.; Schulman, R.N.; Holtzman, D.M. Maternal Dietary Supplementation with Pomegranate Juice Is Neuroprotective in an Animal Model of Neonatal Hypoxic-Ischemic Brain Injury. *Pediatr. Res.* 2005, 57, 885–864. [CrossRef]

37. Li, X.-L.; Hong, M. Aqueous Extract of Dendrobium Officinale Confers Neuroprotection against Hypoxic-Ischemic Brain Damage in Neonatal Rats. *Kaohsiung J. Med. Sci.* 2017, 36, 43–53. [CrossRef]
90. Subash, S.; Essa, M.M.; Asmi, A.; Al-Adawi, S.; Vaishnav, R.; Braidy, N.; Manivasagam, T.; Guillemin, G.J. Pomegranate from Oman Alleviates the Brain Oxidative Damage in Transgenic Mouse Model of Alzheimer’s Disease. *J. Tradit. Complement. Med.* 2014, 4, 232–238. [CrossRef]

91. Ahmed, M.A.E.; El Morsy, E.M.; Ahmed, A.A. Pomegranate extract protects against cerebral ischemia/reperfusion injury and preserves brain DNA integrity in rats. *Life Sci.* 2014. [CrossRef] [PubMed]

92. Sarkaki, A.; Farbood, Y.; Hashemi, S.; Rad, M.R. Pomegranate seed hydroalcoholic extract improves memory deficits in ovariectomized rats with permanent cerebral hypoperfusion/ischemia. *Avicenna J. Phytomed.* 2015, 5, 43–55. [PubMed]

93. Alireza, S.; Moslem, R. Improving active and passive avoidance memories deficits due to permanent cerebral ischemia by pomegranate seed extract in female rats. *Malays. J. Med. Sci.* 2013, 20, 25–34.

94. Rafieirad, M.; Abbaszadeh, H. Pomegranate Seed Extract Reduces Ischemia Induced Anxiety in Male Rats. *J. Herbmed Pharmacol.* 2017, 6, 85–89.

95. Bellone, J.A.; Murray, J.R.; Jorge, P.; Fogel, T.G.; Kim, M.; Wallace, D.R.; Hartman, R.E.; Bellone, J.A.; Murray, J.R.; Jorge, P.; et al. Pomegranate Supplementation Improves Cognitive Function and Recovery Following Ischemic Stroke: A Randomized Trial. *Nutr. Neurosci.* 2019, 22, 738–743. [CrossRef]

96. West, T.; Atzeva, M.; Holtzman, D.M. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. *Dev. Neurosci.* 2007, 29, 363–372. [CrossRef]

97. Basu, A.; Penugonda, K. Pomegranate Juice: A Heart-Healthy Fruit Juice. *Nutr. Rev.* 2009, 67, 49–56. [CrossRef]

98. Gil, I.; Toma, F.A.; Hess-pierce, B.; Holcroft, D.M.; Kader, A.A. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. *J. Agric. Food Chem.* 2000, 48, 4581–4589. [CrossRef]

99. Teixeira da Silva, J.A.; Ng, T.B. The Medicinal and Pharmaceutical Importance of Dendrobium Species. *Appl. Microbiol. Biotechnol.* 2017, 101, 2227–2239. [CrossRef]

100. Ng, T.B.; Liu, J.; Wong, J.H.; Ye, X.; Wing Sze, S.C.; Tong, Y.; Zhang, K.Y. Review of Research on Dendrobium, a Prized Folk Medicine. *Appl. Microbiol. Biotechnol.* 2012, 93, 1795–1803. [CrossRef]

101. Tang, H.; Zhao, T.; Sheng, Y.; Zheng, T.; Fu, L.; Zhang, Y. Dendrobium Officinale Kimura et Migo: A Review on Its Ethnopharmacology, Phytochemistry, Pharmacology, and Industrialization. *Evid. Based Complement. Altern. Med.* 2017, 2017, 7436259. [CrossRef] [PubMed]

102. Koo, K.A.; Sung, S.H.; Park, J.H.; Kim, S.H.; Lee, K.Y.; Kim, Y.C. In Vitro Neuroprotective Activities of Phenylethanoid Glycosides from Callicarpa Dichotoma. *Planta Med.* 2005, 71, 778–780. [CrossRef] [PubMed]

103. Alipieva, K.; Korkina, L.; Erdogan, I.; Georgiev, M.I. Verbascoside—A review of its occurrence, (bio) synthesis and pharmacological significance. *Biotechnol. Adv.* 2014, 32, 1065–1076. [CrossRef] [PubMed]

104. Taylor, P.; He, J.; Hu, X.; Zeng, Y.; Li, Y.; Wu, H.; Qiu, R.; Ma, W.; Li, T.; Li, C.; et al. Advanced Research on Acteoside for Chemistry and Bioactivities. *J. Asian Nat. Prod. Res.* 2011, 37–41. [CrossRef]

105. Imperio, M.D.; Cardinali, A.; Antuono, I.D.; Linsalata, V.; Minervini, F.; Redan, B.W.; Ferruzzi, M.G. Stability—Activity of Verbascoside, a Known Antioxidant Compound, at Different PH Conditions. *Food Res. Int.* 2014, 66, 373–378. [CrossRef]

106. Frum, Y.; Viljoen, A.M.; Van Heerden, F.R. Verbascoside and luteolin-5-3-β-d-glucoside isolated from *Halleria lucida* L. exhibit antagonistic anti-oxidant properties in vitro. *S. Afr. J. Bot.* 2007, 73, 583–587. [CrossRef]

107. Lee, J.H.; Lee, J.Y.; Kang, H.S.; Jeong, C.H.; Moon, H.; Whang, W.K.; Kim, C.J.; Sim, S.S. The Effect of Acteoside on Histamine Release and Arachidonic Acid Release in RBL-2H3 Mast Cells. *Arch. Pharmacal Res.* 2006, 29, 508–513. [CrossRef]

108. speranza, L.; Franceschelli, S.; Pesce, M.; Reale, M.; Mengolini, L.; Vinciguerra, I.; De Lutiis, M.A.; Braidy, N.; Ferruzzi, M.G. Stability—Activity of Verbascoside, a Known Antioxidant Compound, at Different PH Conditions. *Food Res. Int.* 2014, 66, 373–378. [CrossRef]

109. Lee, J.H.; Lee, J.Y.; Kang, H.S.; Jeong, C.H.; Moon, H.; Whang, W.K.; Kim, C.J.; Sim, S.S. The Effect of Acteoside on Histamine Release and Arachidonic Acid Release in RBL-2H3 Mast Cells. *Arch. Pharmacal Res.* 2006, 29, 508–513. [CrossRef]

110. speranza, L.; Franceschelli, S.; Pesce, M.; Reale, M.; Mengolini, L.; Vinciguerra, I.; De Lutiis, M.A.; Braidy, N.; Ferruzzi, M.G. Stability—Activity of Verbascoside, a Known Antioxidant Compound, at Different PH Conditions. *Food Res. Int.* 2014, 66, 373–378. [CrossRef]

111. Lee, J.H.; Lee, J.Y.; Kang, H.S.; Jeong, C.H.; Moon, H.; Whang, W.K.; Kim, C.J.; Sim, S.S. The Effect of Acteoside on Histamine Release and Arachidonic Acid Release in RBL-2H3 Mast Cells. *Arch. Pharmacal Res.* 2006, 29, 508–513. [CrossRef]

112. speranza, L.; Franceschelli, S.; Pesce, M.; Reale, M.; Mengolini, L.; Vinciguerra, I.; De Lutiis, M.A.; Braidy, N.; Ferruzzi, M.G. Stability—Activity of Verbascoside, a Known Antioxidant Compound, at Different PH Conditions. *Food Res. Int.* 2014, 66, 373–378. [CrossRef]

113. Wu, J.; Huang, F.X.; Wang, J.; Shi, C.C.; Fang, G.Y. Protective Effect of Liquiritin on Corticosterone-Induced Neurotoxicity in PC12 Cells. *Trop. J. Pharm. Res.* 2018, 17, 2013–2017. [CrossRef]

114. Yuan, J.; Ren, J.; Wang, Y.; He, X.; Zhao, Y. Acteoside Binds to Caspase-3 and Exerts Neuroprotection in the Rotenone Rat Model of Parkinson’s Disease. *PLoS ONE* 2016, 11, e0162696. [CrossRef] [PubMed]

115. Wei, W.; Lu, M.; Lan, X.; Liu, N.; Wang, H.; Du, J.; Sun, T.; Li, Y.; Yu, J. Neuroprotective Effect of Verbascoside on Hypoxic-Ischemic Brain Damage in Neonatal Rat. *Neurosci. Lett.* 2019, 711, 134415. [CrossRef]

116. Inda, B.D.; Ebnath, S.D.; Anik, R.B. Naturally Occurring Iridoids and Secoiridoids. An Updated Review, Part 4. *Chem. Pharm. Bull.* 2011, 59, 803–833.

117. El-Naggar, I.J.; Beal, J.I. Iridoids. A review. *J. Nat. Prod.* 1980, 43, 649–707. [CrossRef]

118. Chou, G.; Wang, Z.; Medica, C.M.; Park, Z.H. Iridoid glycosides from Gardenia jasminoides Ellis. *Helv. Chim. Acta* 2008, 91, 4–10.
145. Lakhanpal, P.; Rai, D.K. Quercetin: A versatile flavonoid. Internet J. Med. Update 2007, 2, 22–37. [CrossRef]
146. Erden Inal, M.; Kahraman, A. The Protective Effect of Flavonol Quercetin against Ultraviolet a Induced Oxidative Stress in Rats. Toxicology 2000, 154, 21–29. [CrossRef]
147. Shutenko, Z.; Henry, Y.; Pinard, E.; Seylaz, J.; Potier, P.; Berthet, F.; Girard, P.; Sercombe, R. Influence of the Antioxidant Quercetin in Vivo on the Level of Nitric Oxide Determined by Electron Paramagnetic Resonance in Rat Brain during Global Ischemia and Reperfusion. Biochem. Pharmacol. 1999, 57, 199–208. [CrossRef]
148. Huk, I.; Brovkovych, V.; Nanobash Vili, J.; Weigel, G.; Neumayer, C.; Partyka, L.; Patton, S.; Malinski, T. Bioflavonoid Quercetin Scavenges Superoxide and Increases Nitric Oxide Concentration in Ischaemia-Reperfusion Injury: An Experimental Study. Br. J. Surg. 1998, 85, 1080–1085. [CrossRef]
149. Du, G.; Zhao, Z.; Chen, Y.; Li, Z.; Tian, Y.; Liu, Z.; Liu, B.; Song, J. Quercetin Attenuates Neuronal Autophagy and Apoptosis in Rat Traumatic Brain Injury Model via Activation of PI3K/Akt Signaling Pathway. Neurrol. Res. 2016, 38, 1012–1019. [CrossRef]
150. Lei, X.; Chao, H.; Zhang, Z.; Lv, J.; Li, S.; Wei, H.; Xue, R.; Li, F.; Li, Z. Neuroprotective Effects of Quercetin in a Mouse Model of Brain Ischemic/Reperfusion Injury via Anti-Apoptotic Mechanisms Based on the Akt Pathway. Mol. Med. Rep. 2015, 12, 3688–3696. [CrossRef]
151. Hwang, I.K.; Lee, C.H.; Yoo, K.Y.; Choi, J.H.; Park, O.K.; Lim, S.S.; Kang, I.J.; Kwon, D.Y.; Park, J.; Yi, J.S.; et al. Neuroprotective Effects of Onion Extract and Quercetin against Ischemic Neuronal Damage in the Gerbil Hippocampus. J. Med. Food 2009, 12, 990–995. [CrossRef] [PubMed]
152. Wang, X.Q.; Yao, R.Q.; Liu, X.; Huang, J.J.; Qi, D.S.; Yang, L.H. Quercetin Protects Oligodendrocyte Precursor Cells from Oxygen/Glucose Deprivation Injury in Vitro via the Activation of the PI3K/Akt Signaling Pathway. Brain Res. Bull. 2011, 86, 277–284. [CrossRef] [PubMed]
153. Kang, C.H.; Choi, Y.H.; Moon, S.K.; Kim, W.J.; Kim, G.Y. Quercetin Inhibits Lipopolysaccharide-Induced Nitric Oxide Production in BV2 Microglial Cells by Suppressing the NF-κB Pathway and Activating the Nrf2-Dependent HO-1 Pathway. Int. Immunopharmacol. 2013, 17, 808–813. [CrossRef] [PubMed]
154. Yao, R.Q.; Qi, D.S.; Yu, H.L.; Liu, J.; Yang, L.H.; Wu, X.X. Quercetin Attenuates Cell Apoptosis in Focal Cerebral Ischemia Rat Brain via Activation of BDNF-TrkB-PI3K/Akt Signaling Pathway. Neurochem. Res. 2012, 37, 2777–2786. [CrossRef] [PubMed]
155. Ahmad, A.; Khan, M.M.; Hoda, M.N.; Raza, S.S.; Patel, S.; Malinski, T. Bioflavonoid Quercetin Scavenges Superoxide and Increases Nitric Oxide Concentration in Ischaemia-Reperfusion Injury: An Experimental Study. Br. J. Surg. 1998, 85, 1080–1085. [CrossRef]
156. McCormack, D.; McFadden, D. A Review of Pterostilbene Antioxidant Activity and Disease Modification. Oxid. Med. Cell. Longev. 2013, 2013, 85, 21–29. [CrossRef]
157. Roupe, K.A.; Remsberg, C.M.; Yañez, J.A.; Davies, N.M. Pharmacometrics of Stilbenes: Seguing Towards the Clinic. Curr. Clin. Pharmacol. 2006, 1, 81–105. [CrossRef]
158. Ghosh, A.; Sarkar, S.; Mandal, A.K.; Das, N. Neuroprotective Role of Nanoencapsulated Quercetin in Combating Ischemia-Reperfusion Induced Neuronal Damage in Young and Aged Rats. PLoS ONE 2013, 8, e57735. [CrossRef]
159. Qu, X.; Qi, D.; Dong, F.; Wang, B.; Guo, R.; Luo, M.; Yao, R. Quercetin Improves Hypoxia-Ischemia Induced Cognitive Deficits via Promoting Remyelination in Neonatal Rat. Brain Res. 2014, 1535, 31–40. [CrossRef]
160. Wu, M.; Liu, F.; Guo, Q. Quercetin Attenuates Hypoxia-Ischemia Induced Brain Injury in Neonatal Rats by Inhibiting TLR4/NF-κB Signaling Pathway. Int. Immunopharmacol. 2019, 74, 105704. [CrossRef]
161. Adrian, M.; Jeandet, P.; Douillet-Breuil, A.C.; Tesson, L.; Bessis, R. Stilbene Content of Mature Vitis Vinifera Berries in Response to UV-C Elicitation. J. Agric. Food Chem. 2000, 48, 6103–6105. [CrossRef] [PubMed]
162. Roupe, K.A.; Remsberg, C.M.; Yañez, J.A.; Davies, N.M. Pharmacometrics of Stilbenes: Seguing Towards the Clinic. Curr. Clin. Pharmacol. 2006, 1, 81–105. [CrossRef]
163. Jeandet, P.; Clément, C.; Courrot, E.; Cordelier, S. Modulation of Phytoalexin Biosynthesis in Engineered Plants for Disease Resistance. Int. J. Mol. Sci. 2013, 14, 14136–14170. [CrossRef] [PubMed]
164. Liu, J.; Fan, C.; Yu, L.; Yang, Y.; Jiang, S.; Ma, Z.; Hu, W.; Li, T.; Yang, Z.; Tian, T.; et al. Pterostilbene Exerts an Anti-Inflammatory Effect via Regulating Endoplasmic Reticulum Stress in Endothelial Cells. Cytokine 2016, 77, 88–97. [CrossRef] [PubMed]
165. McCormack, D.; McFadden, D. A Review of Pterostilbene Antioxidant Activity and Disease Modification. Oxid. Med. Cell. Longev. 2013, 2013, 85, 21–29. [CrossRef]
166. Remsberg, C.M.; Yañez, J.A.; Ohgami, Y.; Vega-villa, K.R.; Rimando, A.M.; Davies, N.M. Pharmacometrics of Pterostilbene: Preclinical Pharmacokinetics and Metabolism, Anticancer, Anti-Inflammatory, Antioxidant and Analogic Activity. Phytotherapy Res. 2008, 19, 679–685. [CrossRef]
167. Hou, Y.; Xie, G.; Miao, F.; Ding, L.; Mou, Y.; Wang, L.; Su, G.; Chen, G.; Yang, J.; Wu, C. Pterostilbene Attenuates Lipopolysaccharide-Induced Learning and Memory Impairment Possibly via Inhibiting Microglia Activation and Protecting Neuronal Injury in Mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48, 1–11. [CrossRef]
168. Chang, J.; Rimando, A.; Pallas, M.; Camins, A.; Porquet, D.; Reeves, J.; Shukitt-hale, B.; Smith, M.A.; Joseph, J.A.; Casadesus, G. Low-Dose Pterostilbene, but Not Resveratrol, Is a Potent Neuromodulator in Aging and Alzheimer’s Disease. NBA 2012, 33, 2062–2071. [CrossRef]
169. Papers. O. Anxiolytic Action of Pterostilbene: Involvement of Hippocampal ERK Phosphorylation. Planta Med. 2013, 79, 723–730.
170. Yang, Y.; Wang, J.; Li, Y.; Fan, C.; Jiang, S.; Zhao, L.; Di, S.; Xin, Z.; Wang, B.; Wu, G.; et al. HO-1 Signaling Activation by Pterostilbene Treatment Attenuates Mitochondrial Oxidative Damage Induced by Cerebral Ischemia Reperfusion Injury. Mol. Neurobiol. 2015. [CrossRef] [PubMed]

171. Zhou, Y.; Zhang, X.; Ma, A.; Zhang, Y.; Chen, Y.; Zhou, H.; Li, W.; Jin, X. Orally Administered Pterostilbene Attenuates Acute Cerebral Ischemia—Reperfusion Injury in a Dose- and Time-Dependent Manner in Mice. Pharmacol. Biochem. Behav. 2015, 135, 199–209. [CrossRef] [PubMed]

172. Li, D.; Song, T.; Yang, L.; Wang, X.; Yang, C.; Jiang, Y. Neuroprotective Actions of Pterostilbene on Hypoxic-Ischemic Brain Damage in Neonatal Rats through Upregulation of Heme Oxygenase-1. Int. J. Dev. Neurosci. 2016, 54, 22–31. [CrossRef] [PubMed]

173. Zhou, Y.; Liu, Y.E.; Cao, J.; Zeng, G.; Shen, C.; Zhou, M.; Chen, Y.; Pu, W.; Potters, L.; Shi, E.Y. Vitexins, nature-derived lignan compounds, induce apoptosis and suppress tumor growth. Clin. Cancer Res. 2010, 15, 5161–5169. [CrossRef] [PubMed]

174. Zucolotto, S.M.; Fagundes, C.; Reginatto, F.H.; Ramos, F.A.; Castellanos, L.; Duque, C.; Schenkel, E.P. Analysis of C-Glycosyl Flavonoids from South American Passiflora Species by HPLC-DAD and HPLC-MS. Phytochem. Anal. 2012, 23, 232–239. [CrossRef]

175. Zhang, J.; Yuan, K.; Zhou, W.L.; Zhou, J.; Yang, P. Studies on the Active Components and Antioxidant Activities of the Extracts of Mimosa Pudica Linn. from Southern China. Pharmagron. Mag. 2011, 7, 35–39. [CrossRef] [PubMed]

176. Moheb, A.; Ibrahim, R.K.; Roy, R.; Sarhan, F. Changes in Wheat Leaf Phenolome in Response to Cold Acclimation. Phytochemistry 2011, 72, 2294–2307. [CrossRef] [PubMed]

177. Ma, L.Y.; Liu, R.H.; Xu, X.D.; Yu, M.Q.; Zhang, Q.; Liu, H.L. The Pharmacokinetics of C-Glycosyl Flavones of Hawthorn Leaf Flavonoids in Rat after Single Dose Oral Administration. Phytochemistry 2010, 71, 640–645. [CrossRef]

178. Zhou, J.; Hu, H.; Long, J.; Wan, F.; Li, L.; Zhang, S.; Shi, Y.E.; Chen, Y. Vitexin 6, a Novel Lignan, Induces Autophagy and Apoptosis by Activating the Jun N-Terminal Kinase Pathway. Anticancer Drugs 2013, 24, 928–936. [CrossRef]

179. Li, Y.L.; Ma, S.C.; Yang, Y.T.; Ye, S.M.; But, P.P.H. Antiviral Activities of Flavonoids and Organic Acid from Trollius Chinensis Bunge. J. Ethnopharmacol. 2002, 79, 365–368. [CrossRef]

180. Dong, L.; Fan, Y.; Shao, X.; Chen, Z. Vitexin Protects against Myocardial Ischemia/Reperfusion Injury in Langendorff-Perfused Rat Hearts by Attenuating Inflammatory Response and Apoptosis. Food Chem. Toxicol. 2011, 49, 3211–3216. [CrossRef]

181. Dong, L.Y.; Li, S.; Zhen, Y.L.; Wang, Y.N.; Shao, X.; Luo, Z.G. Cardioprotection of Vitexin on Myocardial Ischemia/Reperfusion Injury in Rat via Regulating Inflammatory Cytokines and MAPK Pathway. Am. J. Chin. Med. 2013, 41, 1251–1266. [CrossRef] [PubMed]

182. Can, O.D.; Demir Özkay, Ü.; Üçel, U.I. Anti-Depressant-like Effect of Vitexin in BALB/c Mice and Evidence for the Involvement of Monoaminergic Mechanisms. Eur. J. Pharmacol. 2013, 699, 250–257. [CrossRef] [PubMed]

183. Abbasi, E.; Nassiri-Asl, M.; Shafeei, M.; Sheikh, M. Neuroprotective Effects of Vitexin, a Flavonoid, on Pentyleneetrazole-Induced Seizure in Rats. Chem. Biol. Drug Des. 2012, 80, 274–278. [CrossRef] [PubMed]

184. Abbasi, E.; Nassiri-Asl, M.; Sheikh, M.; Shafeei, M. Effects of Vitexin on Scopolamine-Induced Memory Impairment in Rats. Chin. J. Physiol. 2013, 56, 184–189. [CrossRef] [PubMed]

185. Yang, L.; Yang, Z.M.; Zhang, N.; Tian, Z.; Liu, S.B.; Zhao, M.G. Neuroprotective Effects of Vitexin by Inhibition of NMDA Receptors in Primary Cultures of Mouse Cerebral Cortical Neurons. Mol. Cell. Biochem. 2014, 386, 251–258. [CrossRef] [PubMed]

186. Wang, Y.; Zhen, Y.; Wu, X.; Jiang, Q.; Li, X.; Chen, Z.; Zhang, G.; Dong, L. Vitexin Protects Brain against Ischemia/Reperfusion Injury via Modulating Mitogen-Activated Protein Kinase and Apoptosis Signaling in Mice. Phytotherapy 2015, 22, 379–384. [CrossRef] [PubMed]

187. Choi, H.J.; Eun, J.S.; Kim, B.G.; Kim, S.Y.; Jeon, H.; Soh, Y. Vitexin, an HIF-1α Inhibitor, Has Anti-Metastatic Potential in PC12 cells. Mol. Cells 2006, 22, 291–299. [CrossRef]

188. Min, J.W.; Hu, J.J.; He, M.; Sanchez, R.M.; Huang, W.X.; Liu, Y.Q.; Bsoon, N.B.; Han, S.; Yin, J.; Liu, W.H.; et al. Vitexin Reduces Hypoxia-Ischemia Neonatal Brain Injury by the Inhibition of HIF-1α in a Rat Pup Model. Neuropharmacology 2015, 99, 38–50. [CrossRef]

189. Funaya, N.; Haginaka, J. Matrine- and Oxy-matrine-Imprinted Monodisperse Polymers Prepared by Precipitation Polymerization and Their Applications for the Selective Extraction of Matrine-Type Alkaloids from Sophora Flavescens Aiton. J. Chromatogr. A 2012, 1248, 18–23. [CrossRef]

190. Guzman, J.R.; Koo, J.S.; Goldsmith, J.R.; Mühlbauer, M.; Narula, A.; Jobin, C. Oxy-matrine Prevents NF-KB Nuclear Translocation and Ameliorates Acute Intestinal Inflammation. Sci. Rep. 2013, 3, 1–9. [CrossRef]

191. Wang, S.; Jia, J. Oxy-matrine Attenuates Diabetes-Associated Cognitive Deficits in Rats. Acta Pharmacol. Sin. 2014, 35, 331–338. [CrossRef] [PubMed]

192. Ma, Z.J.; Li, Q.; Wang, J.B.; Zhao, Y.L.; Zhong, Y.W.; Bai, Y.F.; Wang, R.L.; Li, J.Y.; Yang, H.Y.; Zeng, L.N.; et al. Combining Oxy-matrine or Matrine with Lamivudine Increased Its Antireplication Effect against the Hepatitis B Virus in Vitro. Evid. Based Complement. Altern. Med. 2013, 2013, 186573. [CrossRef] [PubMed]

193. Papers, O. Protective Effects of Oxy-matrine on Experimental Diabetic Nephropathy. Planta Med. 2014, 80, 269–276. [CrossRef]

194. Chai, N.L.; Fu, Q.; Shi, H.; Cai, C.H.; Wan, J.; Xu, S.P.; Wu, B.Y. Oxy-matrine Liposome Attenuates Hepatic Fibrosis via Targeting Hepatic Stellate Cells. World J. Gastroenterol. 2012, 18, 4199–4206. [CrossRef] [PubMed]

195. Xiao, T.; Wang, Y.; Zhang, Y.; Bai, C.; Shen, X. Similar to Spironolactone, Oxy-matrine Is Protective in Aldosterone-Induced Cardiomyocyte Injury via Inhibition of Calpain and Apoptosis-Inducing Factor Signaling. PLoS ONE 2014, 9, e88856. [CrossRef] [PubMed]
223. Castro, C.C.; Pagnussat, A.S.; Moura, N.; da Cunha, M.J.; Machado, F.R.; Wyse, A.T.S.; Netto, C.A. Coumestrol Treatment Prevents Na+, K+-ATPase Inhibition and Affords Histological Neuroprotection to Male Rats Receiving Cerebral Global Ischemia. *Neuro. Res.* 2014, 36, 198–206. [CrossRef] [PubMed]

224. Beatriz, J.; Anastacio, R.; Farias, E.; Nicola, F.; Odorczyk, F.; Bandeira, R.; Alexandre, C.; Biochemistry, P.P.; Federal, U.; Ufrgs, S.; et al. Phytoestrogen Coumestrol Attenuates Brain Mitochondrial Dysfunction and Long-Term Cognitive Deficits Following Neonatal Hypoxia—Ischemia. *J. Dev. Neurosci.* 2019, 79, 86–95. [CrossRef]

225. Mubarakshina, M.M.; Ivanov, B.N. The Production and Scavenging of Reactive Oxygen Species in the Plastoquinone Pool of Chloroplast Thylakoid Membranes. *Physiol. Plant.* 2010, 140, 103–110. [CrossRef]

226. Borisova-Mubarakshina, M.M.; Vetoshkina, D.V.; Ivanov, B.N. Antioxidant and Signaling Functions of the Plastoquinone Pool in Higher Plants. *Physiol. Plant.* 2019, 166, 181–198. [CrossRef]

227. Amesz, J. The function of plastoquinone in photosynthetic electron transport. *Biochim. Biophys. Acta.* 1973, 301, 35–51. [CrossRef]

228. Ivanov, B.; Khorobrykh, S. Participation of photosynthetic electron transport in production and scavenging of reactive oxygen species. *Antioxid. Redox Signal.* 2003, 5, 43–53. [CrossRef]

229. Skulachev, V.P. A biochemical approach to the problem of aging: “megaproject” on membrane-penetrating ions. The first results and prospects. *Biochemistry 2007*, 72, 1385–1396. [CrossRef]

230. Bakeeva, L.E.; Barskov, I.V.; Egorov, M.V.; Isaev, N.K.; Kapelko, V.I.; Kazachenko, A.V.; Kirpatovskiy, V.I.; Kozlovsky, S.V.; Lakomkin, V.I.; Levine, S.B.; et al. Mitochondria Targeted Plastoquinone Derivatives as Tools to Interrupt Execution of the Aging Program. 2. Treatment of Some ROS and Age Related Diseases (Heart Arrhythmia, Heart Infarctions, Kidney Ischemia, and Stroke). *Biochemistry 2008*, 73, 1288–1299. [CrossRef]

231. Jankauskas, S.S.; Andrianova, N.V.; Alieva, I.B.; Prusov, A.N.; Matsievska, D.D.; Zorova, L.D.; Pevzner, I.B.; Savchenko, E.S.; Pirogov, Y.A.; Silachev, D.N.; et al. Dysfunction of Kidney Endothelium after Ischemia / Reperfusion and Its Prevention by Mitochondria Targeted Antioxidant. *Biochemistry 2016*, 81, 1538–1548. [CrossRef] [PubMed]

232. Plotnikov, E.Y.; Chupyrkina, A.A.; Jankauskas, S.S.; Pevzner, I.B.; Silachev, D.N.; Skulachev, V.P.; Zorov, D.B. Biochimica et Biophysica Acta Mechanisms of Nephroprotective Effect of Mitochondria-Targeted Antioxidants under Rhabdomyolysis and Ischemia/Reperfusion. *Biochim. Biophys. Acta BBA Mol. Basis Dis.* 2011, 1812, 77–86. [CrossRef] [PubMed]

233. Neroev, V.V.; Archipova, M.M.; Bakeeva, L.E.; Fursoya, A.Z.; Grigorian, E.N.; Iomdina, E.N.; Ivashchenko, Z.N.; Katargina, L.A.; Maslova, I.P.K.; et al. Mitochondria Targeted Plastoquinone Derivatives as Tools to Interrupt Execution of the Aging Program. 4. Age Related Eye Disease. SkQ1 Returns Vision to Blind Animals. *Biochemistry 2008*, 73, 1317–1328. [CrossRef] [PubMed]

234. Isaev, N.K.; Novikova, S.V.; Stelmashook, E.V.; Barskov, I.V.; Silachev, D.N.; Khaspekov, L.G.; Skulachev, V.P.; Zorov, D.B. Mitochondria Targeted Plastoquinone Antioxidant SkQ1 Decreases Trauma Induced Neurological Deficit in Rat. *Biochemistry 2012*, 77, 996–999. [CrossRef]

235. Silachev, D.N.; Isaev, N.K.; Pevzner, I.B.; Zorova, L.D. The Mitochondria-Targeted Antioxidants and Remote Kidney Preconditioning Ameliorate Brain Damage through Kidney-to-Brain Cross-Talk. *PLoS ONE* 2012, 7, e51553. [CrossRef]

236. Plotnikov, E.Y.; Silachev, D.N.; Chupyrkina, A.A.; Danshina, M.I.; Jankauskas, S.S.; Morosanova, M.A.; Stelmashook, E.V.; Vasileva, A.K.; Goryacheva, E.S.; Pirogov, Y.A.; et al. New Generation Skulachev Ions Exhibiting Nephroprotective and Neuroprotective Properties. *Biochemistry 2010*, 75, 145–150. [CrossRef]

237. Ischemic, H.; Injuriy, B.; Silachev, D.N.; Plotnikov, E.Y.; Pevzner, I.B.; Zorova, L.D.; Balakireva, A.V.; Id, M.V.G.; Pirogov, Y.A.; Skulachev, V.P.; et al. Neuroprotective effects of mitochondria-targeted plastoquinone and thymoquinone in a rat model of brain ischemia/reperfusion injury. *Molecules* 2015, 20, 14487–14503. [CrossRef]

238. Akinwumi, B.C.; Bordun, K.M.; Anderson, H.D. Biological Activities of Stilbenoids. *Int. J. Mol. Sci.* 2018, 19, 792. [CrossRef]

239. Fernández-Mar, M.I.; Mateos, R.; García-parrilla, M.C.; Puertas, B.; Santos-Villar, E. Bioactive Compounds in Wine: Resveratrol, Hydroxytyrosol and Melatonin: A Review. *Food Chem.* 2012, 130, 797–813. [CrossRef]

240. Sovak, M. Grape Extract, Resveratrol, and Its Analogos: A Review. *J. Med. Food* 2001, 4, 93–105. [CrossRef]

241. Smoliga, J.M.; Baur, J.A.; Hausenblas, H.A. Resveratrol and Health—A Comprehensive Review of Human Clinical Trials. *Mol. Nutr. Food Res.* 2011, 1129–1141. [CrossRef] [PubMed]

242. Cottart, C.H.; Nivet-Antoine, V.; Beaudieux, J.L. Review of Recent Data on the Metabolism, Biological Effects, and Toxicity of Resveratrol in Humans. *Mol. Nutr. Food Res.* 2014, 58, 7–21. [CrossRef] [PubMed]

243. Rauf, A.; Imran, M.; Sulera, H.A.R.; Ahmad, B.; Peters, D.G.; Mubarak, M.S. A Comprehensive Review of the Health Perspectives of Resveratrol. *Food Funct.* 2017, 8, 4284–4305. [CrossRef] [PubMed]

244. Savouret, J.F.; Quesne, M. Resveratrol and Cancer: A Review. *Biomed. Pharmacother.* 2002, 56, 84–87. [CrossRef]

245. Meng, T.; Xiao, D.; Muhammed, A.; Deng, J.; Chen, L.; He, J. Anti-Inflammatory Action and Mechanisms of Resveratrol. *Molecules* 2021, 26, 229. [CrossRef]

246. Neves, A.R.; Lucio, M.; LC Lima, J.; Reis, S. Resveratrol in Medicinal Chemistry: A Critical Review of Its Pharmacokinetics, Drug-Delivery, and Membrane Interactions. *Curr. Med. Chem.* 2012, 19, 1663–1681. [CrossRef]

247. Albani, D.; Polito, L.; Signorini, A.; Forloni, G. Neuroprotective Properties of Resveratrol in Different Neurodegenerative Disorders. *BioFactors* 2010, 36, 370–376. [CrossRef]

248. Bastianetto, S.; Ménard, C.; Quirion, R. Neuroprotective Action of Resveratrol. *Biochim. Biophys. BBA Acta Mol. Basis Dis.* 2015, 1852, 1195–1201. [CrossRef]
249. Richard, T.; Victor, U.; Bordeau, S.; Waffo-téguo, P.; Richard, T.; Pawlus, A.D.; Igl, M.; Pedrot, E.; Waffo-téguo, P. Neuroprotective Properties of Resveratrol and Derivatives. Neuroprotective Properties of Resveratrol and Derivatives. Ann. N.Y. Acad. Sci. 2011. [CrossRef]

250. Tellone, E.; Galtieri, A.; Russo, A.; Giardina, B.; Ficarra, S. Resveratrol: A Focus on Several Neurodegenerative Diseases. Oxid. Med. Cell Longev. 2015, 2015, 392169. [CrossRef]

251. Pallàs, M.; Casadesús, G.; Smith, M.A.; Coto-montes, A.; Pelegri, C.; Vilaplana, J.; Camins, A. Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection. Curr. Neurovasc. Res. 2009, 6, 70–81. [CrossRef] [PubMed]

252. Granados-Soto, V. Resveratrol: A Natural Compound with Pharmacological Potential in Neurodegenerative Diseases. CNS Neurosci. Thera. 2008, 14, 14–234. [CrossRef]

253. Regé, S.D.; Geetha, T.; Griffin, G.D.; Broderick, T.L.; Babu, J.R. Neuroprotective Effects of Resveratrol in Alzheimer Disease Pathology. Front. Aging Neurosci. 2014, 6, 1–27. [CrossRef] [PubMed]

254. Gomes, Q.; Alexandre, B.; Paulo, J.; Silva, B.; Fernanda, C.; Romeiro, R.; Monteiro, S.; Rodrigues, C.A.; Gonçalves, P.R.; Sakai, J.T.; et al. Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1. Oxid. Med. Cell Longev. 2018, 2018, 8152373. [CrossRef]

255. Singh, N.; Agrawal, M.; Dore, S. Neuroprotective Functions and Mechanisms of Resveratrol in in Vitro and in Vivo Experimental Cerebral Stroke Models. ACS Chem. Neurosci. 2013, 4, 1151–1162. [CrossRef]

256. Lopez, M.S.; Dempsey, R.J.; Vemuganti, R. Resveratrol Neuroprotection in Stroke and Traumatic CNS Injury. Neurochem. Int. 2015. [CrossRef]

257. Dave, K.R.; Fazio, R.A.D.E.; Bao, Y.C.; Raval, A.P. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1—Uncoupling protein 2 pathway. Neuroscience 2009, 159, 993–1002. [CrossRef]

258. Dong, W.; Li, N.; Gao, D.; Zhen, H. Resveratrol Attenuates Ischemic Brain Damage in the Delayed Phase after Stroke and Induces Messenger RNA and Protein Express for Angiogenic Factors. J. Vasc. Surg. 2008, 48, 709–714. [CrossRef]

259. Lei, J.R.; Tu, X.K.; Wang, Y.; Tu, D.W.; Shi, S.S. Resveratrol Downregulates the TLR4 Signaling Pathway to Reduce Brain Damage in a Rat Model of Focal Cerebral Ischemia. Exp. Ther. Med. 2019, 3215–3221. [CrossRef]

260. Suo, S.; Cheng, M.; Lien, C. Resveratrol Reduction of Infarct Size in Long-Evans Rats Subjected to Focal Cerebral Ischemia. Life Sci. 2001, 69, 1057–1065.

261. Li, Z.; Pang, L.; Fang, F.; Zhang, G.; Zhang, J.; Xie, M.; Wang, L. Resveratrol Attenuates Brain Damage in a Rat Model of Focal Cerebral Ischemia via Up-Regulation of VEGF. Brain Res. 2012, 1450, 116–124. [CrossRef] [PubMed]

262. Hong, J.; Lee, H.; Lee, S. Protective effect of resveratrol against neuronal damage following transient global cerebral ischemia in mice. J. Nutr. Biochem. 2015. [CrossRef] [PubMed]

263. Wang, Q.; Xu, J.; Rottinghaus, G.E.; Simonyi, A.; Lubahn, D.; Sun, G.Y.; Sun, A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 2002, 958, 439–447. [CrossRef]

264. Gao, D.; Zhang, X.; Jiang, X.; Peng, Y.; Huang, W.; Cheng, G.; Song, L. Resveratrol Reduces the Elevated Level of MMP-9 Induced by Cerebral Ischemia—Reperfusion in Mice. Life Sci. 2006, 78, 2564–2570. [CrossRef] [PubMed]

265. He, Q.; Li, Z.; Wang, Y.; Hou, Y.; Li, L.; Zhao, J. Resveratrol Alleviates Cerebral Ischemia/Reperfusion Injury in Rats by Inhibiting NLRP3 Inflammasome Activation through Sirtuin1-Dependent Autophagy Induction. Int. Immunopharmacol. 2017, 50, 208–215. [CrossRef]

266. Kizmazoglu, C.; Aydin, H.E.; Kalemci, O.; Yuceer, N.; Atasoy, M.A. Neuroprotective Effect of Resveratrol on Acute Brain Ischemia Reperfusion Injury by Measuring Annexin V, P53, Bcl-2 Levels in Rats. J. Korean Neurosurg. Soc. 2015, 58, 508–512. [CrossRef]

267. Abdel-Aleem, G.A.; Khaleel, E.F.; Mostafa, D.G.; Elberier, L.K. Neuroprotective effect of resveratrol against brain ischemia reperfusion injury in rats entails reduction of DJ-1 protein expression and activation of PI3K/Akt/GSK3b survival pathway. Arch. Physiol. Biochem. 2016, 3455. [CrossRef]

268. Kovacic, P.; Somanathan, R. Multifaceted Approach to Resveratrol Bioactivity Focus on Antioxidant Action, Cell Signaling and Safety. Oxid. Med. Cell. Longev. 2010, 3, 86–100. [CrossRef]

269. Science, F. Neuroprotective Effects of Resveratrol on Cerebral Ischemia-Induced Neuron Loss Mediated by Free Radical Scavenging and Cerebral Blood Flow Elevation. J. Agric. Food Chem. 2006, 54, 3126–3131.

270. Poulsen, M.M.; Fjeldborg, K.; Ormstrup, M.J.; Kjær, T.N.; Nohr, M.K.; Pedersen, S.B. Resveratrol and Inflammation: Challenges in Translating Pre-Clinical Findings to Improved Patient Outcomes. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2015. [CrossRef]

271. Zhang, F.; Liu, J.; Shi, J. Anti-Inflammatory Activities of Resveratrol in the Brain: Role of Resveratrol in Microglial Activation. Eur. J. Pharmacol. 2010, 636, 1–7. [CrossRef] [PubMed]

272. Fulda, S.; Debatin, K.M. Resveratrol Modulation of Signal Transduction in Apoptosis and Cell Survival: A Mini-Review. Cancer Detect. Prev. 2006, 30, 217–223. [CrossRef] [PubMed]

273. Shin, J.Y.; Seoul, M.A.; Choi, E.J.; Kim, J.K.; Seoul, E.S.; Lee, J.H.; Chung, H.L.; Kim, W.T. Neuroprotective effects of resveratrol via anti-apoptosis on hypoxic-ischemic brain injury in neonatal rats. Korean J. Pediatr. 2008, 51, 1102–1111. [CrossRef]

274. Karalis, F.; Soubasi, V.; Georgiou, T.; Nakas, C.T.; Simeonidou, C.; Guiba-Tziampiri, O.; Spandou, E. Resveratrol Ameliorates Hypoxia/Ischemia-Induced Behavioral Deficits and Brain Injury in the Neonatal Rat Brain. Brain Res. 2011, 1425, 98–110. [CrossRef] [PubMed]
299. Deslandes, A.C.; Veiga, H.; Cagy, M.; Piedade, R.; Pompeu, F.; Ribeiro, P. Effects of Caffeine on the Electrophysiological, Cognitive and Motor Responses of the Central Nervous System. Braz. J. Med. Biol. Res. 2005, 38, 1077–1086. [CrossRef]
300. Comer, A.M.; Ferry, C.M.; Figgitt, D.P.; Bhatia, J.; Neonatology, S.; College. M. Caffeine Citrate: A Review of Its Use in Apnoea of Prematurity. Paediatr Drugs. 2001, 3, 61–79. [CrossRef]
301. Schmidt, B.; Roberts, R.S.; Davis, P.; Doyle, L.W.; Barrington, K.J.; Ohlsson, A.; Solimano, A.; Tin, W. Caffeine Therapy for Apnea of Prematurity. N. Engl. J. Med. 2006, 2112–2121. [CrossRef]
302. Picone, S.; Bedetta, M.; Paolillo, P. Caffeine Citrate: When and for How Long. A Literature Review. J. Matern. Neonatal Med. 2012, 25, 11–14. [CrossRef]
303. Back, S.A.; Craig, A.; Luo, N.L.; Ren, J.; Akundi, R.S.; Ribeiro, I.; Rivkees, S.A. Protective Effects of Caffeine on Chronic Hypoxia-Induced Perinatal White Matter Injury. Ann. Neurol. 2006, 3, 695–705. [CrossRef] [PubMed]
304. Kilicdag, H.; Daglioglu, Y.K.; Erdogan, S.; Zorludemir, S. Effects of Caffeine on Neuronal Apoptosis in Neonatal Hypoxic-Ischemic Brain Injury. Ann. Neurol. 2014, 7058, 1470–1475. [CrossRef] [PubMed]
305. Hoda, S.; Hosseinzadeh, H. Bioactivity Assessment and Toxicity of Crocin: A Comprehensive Review. Food Chem. Toxicol. 2014, 64, 65–80. [CrossRef]
306. Abdel-Rahman, R.F.; El Awdan, S.A.; Hegazy, R.R.; Mansour, D.F.; Ogaly, H.A.; Abdelbaset, M. Neuroprotective Effect of Crocus Sativus against Cerebral Ischemia in Rats. Metab. Brain Dis. 2020, 427–439. [CrossRef] [PubMed]
307. Sarshoori, J.R.; Asadi, M.H.; Mohammadi, M.T. Neuroprotective Effects of Crocin on the Histopathological Alterations Following Brain Ischemia-Reperfusion Injury in Rat. Iran. J. Basic Med. Sci. 2014, 17, 895. [PubMed]
308. Pitsikas, N.; Sakellaridis, N. Crocus sativus L. extracts antagonize memory impairments in different behavioural tasks in the rat. Behav. Brain Res. 2006, 173, 112–115. [CrossRef] [PubMed]
309. Wang, K.; Zhang, L.; Rao, W.; Su, N.; Hui, H.; Wang, L.; Peng, C.; Tu, Y.; Zhang, S.; Fei, Z. Neuroprotective Effects of Crocin against Traumatic Brain Injury in Mice: Involvement of Noot Signaling Pathway. Neurosci. Lett. 2015, 591, 53–58. [CrossRef] [PubMed]
310. Hassani, F.V.; Naseri, V.; Razavi, B.M.; Mehri, S.; Abnous, K. Antidepressant Effects of Crocin and Its Effects on Transcript and Protein Levels of CREB, BDNF, and VGF in Rat Hippocampus. DARU J. Pharm. Sci. 2014, 22, 1–9.
311. Huang, A.; Jia, L. Crocin Enhances Hypothermia Therapy in Hypoxic Ischemia-Induced Brain Injury in Mice. Acta Neurol. Belg. 2019. [CrossRef]
312. Xu, S.; Liu, P. Tanshinone II-A: New Perspectives for Old Remedies. Expert Opin. Ther. Pat. 2013, 23, 149–153. [CrossRef] [PubMed]
313. Gao, S.; Liu, Z.; Li, H.; Little, P.J.; Liu, P.; Xu, S. Cardiovascular Actions and Therapeutic Potential of Tanshinone II A. Atherosclerosis 2012, 220, 3–10. [CrossRef] [PubMed]
314. Shang, Q.; Xu, H.; Huang, L. Tanshinone II A: A Promising Natural Cardioprotective Agent. Evid. Based Complement. Altern. Med. 2012, 2012, 716459. [CrossRef] [PubMed]
315. Zhang, Y.; Jiang, P.; Ye, M.; Kim, S.H.; Jiang, C.; Lü, J. Tanshinones: Sources, Pharmacokinetics and Anti-Cancer Activities. Int. J. Mol. Sci. 2012, 13, 13621–13666. [CrossRef]
316. Niu, X.L.; Ichimori, K.; Yang, X.; Hirota, Y.; Hoshiai, K.; Li, M.; Nakazawa, H. Tanshinone II-A Inhibits Low Density Lipoprotein Oxidation in Vitro. Free Radic. Res. 2000, 33, 305–312. [CrossRef]
317. Zhou, Z.Y.; Zhao, W.R.; Zhang, J.; Chen, X.L.; Tang, J.Y. Sodium Tanshinone II A Sulfonate: A Review of Pharmacological Activity and Pharmacokinetics. Biomed. Pharmacother. 2019, 118, 109362. [CrossRef]
318. Chen, Y.; Wu, X.; Yu, S.; Lin, X.; Wu, J.; Li, L.; Zhao, J.; Zhao, Y. Neuroprotection of Tanshinone II A against Cerebral Ischemia/Reperfusion Injury through Inhibition of Macrophage Migration Inhibitory Factor in Rats. PLoS ONE 2012, 7, e40165. [CrossRef]
319. Ren, Y.; Houghton, P.J.; Hider, R.C.; Howes, M.J.R. Novel Diterpenoid Acetylclohexilalenterase Inhibitors from Salvia Miltiorhiza. Planta Med. 2004, 70, 201–204. [CrossRef]
320. Xia, W.J.; Yang, M.; Fok, T.F.; Li, K.; Chan, W.Y.; Ng, P.C.; Ng, H.K.; Chik, K.W.; Wang, C.C.; Gu, G.J.S.; et al. Partial Neuroprotective Effect of Pretreatment with Tanshinone IIA on Neonatal Hypoxia-Ischemia Brain Damage. Pediatr. Res. 2005, 58, 784–790. [CrossRef]
321. Bowler, C.J. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: Non-psychoactive cannabinoids, ‘entourage’ compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. Brain Res. Rev. 2003, 41, 26–43. [CrossRef]
322. Rosenberg, E.C.; Patra, P.H.; Whalley, B.J. Therapeutic Effects of Cannabinoids in Animal Models of Seizures, Epilepsy, Epileptogenesis, and Epilepsy-Related Neuroprotection. Epilepsy Behav. 2016, 1–9. [CrossRef] [PubMed]
323. Sánchez, A.J.; García-Merino, A. Neuroprotective Agents: Cannabinoids. Clin. Immunol. 2012, 142, 57–67. [CrossRef] [PubMed]
324. Fernández-López, D.; Pazos, M.R.; Tolon, R.M.; Moro, M.A.; Romero, J.; Lizasoain, I.; Martínez-Orgado, J. The cannabinoid agonist WIN555212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatric Res. 2007, 62, 255–260. [CrossRef] [PubMed]
325. Zuardi, A.W.; Crippa, J.A.S.; Hallak, J.E.C.; Bhattacharyya, S.; Martín-Santos, R.; Mcguire, P.K.; Guimaraes, F.S. A Critical Review of the Antipsychotic Effects of Cannabidiol 30 Years of a Trans- Lational Investigation. Curr. Pharm. Des. 2015, 5131–5140. [CrossRef]
326. Scuderi, C.; De Filippis, D.; Iuvone, T.; Blasio, A.; Steardo, A.; Esposito, G. Cannabidiol in Medicine: A Review of Its Therapeutic Potential in CNS Disorders. *Phytotherapy Res.* 2009, 22, 597–602. [CrossRef]

327. Millar, S.A.; Stone, N.L.; Yates, A.S.; Sullivan, S.E.O. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. *Front. Pharmacol.* 2018, 9. [CrossRef]

328. Burstein, S. CBD Receptor Binding Signaling Events Downstream Events. *Bioorg. Med. Chem.* 2015. [CrossRef]

329. Alvarez, F.J.; Lafuente, H.; Rey-santano, M.C.; Mielgo, V.E.; Gastiasoro, E.; Rueda, M.; Pertwee, R.G.; Castillo, A.I.; Romero, J.; Martínez-Orgado, J. Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets. *Pediatr. Res.* 2008, 64, 653–658. [CrossRef]

330. Castillo, A.; Tolón, M.R.; Fernández-Ruiz, J.; Romero, J.; Martínez-Orgado, J. Neurobiology of Disease The Neuroprotective Effect of Cannabidiol in an in Vitro Model of Newborn Hypoxic—Ischemic Brain Damage in Mice Is Mediated by CB2 and Adenosine Receptors. *Neurobiol. Dis.* 2010, 37, 434–440. [CrossRef]

331. Lafuente, H.; Alvarez, F.J.; Pazos, M.R.; Alvarez, A.; Rey-Santano, M.C.; Mielgo, V.; Murgia-Esteve, X.; Hilario, E.; Martínez-Orgado, J. Cannabidiol Reduces Brain Damage and Improves Functional Recovery after Acute Hypoxia-Ischemia in Newborn Pigs. *Pediatr. Res.* 2011, 70, 272–277. [CrossRef]

332. Pazos, M.R.; Cinquina, V.; Gómez, A.; Layunta, R.; Santos, M.; Fernández-ruiz, J.; Martínez-orgado, J. Cannabidiol administration after hypoxia e ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. *Neuropharmacology 2012, 63, 776–783.* [CrossRef] [PubMed]

333. Pazos, M.R.; Mohammed, N.; Lafuente, H.; Santos, M.; Martín-pinilla, E.; Moreno, E.; Valdizan, E.; Romero, J.; Pazos, A.; Franco, R.; et al. Mechanisms of Cannabidiol Neuroprotection in Hypoxic Ischemic Newborn Pigs: Role of 5HT1A and CB2 Receptors. *Neuropharmacology 2013, 71, 282–291.* [CrossRef] [PubMed]

334. Barata, L.; Arruza, L.; Rodríguez, M.; Aleo, E.; Vierge, E.; Criado, E.; Sobrino, E.; Vargas, C.; Ceprián, M.; Gutiérrez-Rodríguez, A.; et al. Neuroprotection by Cannabidiol and Hypothermia in a Piglet Model of Newborn Hypoxic-Ischemic Brain Damage. *Neuropharmacology 2019, 146, 1–11.* [CrossRef] [PubMed]

335. Ferreira, A.; Rodrigues, M.; Fortuna, A.; Falcão, A.; Alves, G. Huperzine A from Huperzia Serrata: A Review of Its Sources, Chemistry, Pharmacology and Toxicology. *Phytomedicine 2016, 15, 51–85.* [CrossRef]

336. Desilets, A.R.; Gickas, J.J.; Duncan, K.C. Role of Huperzine A in the Treatment of Alzheimer’s Disease. *Ann. Pharmacother.* 2009, 43. [CrossRef] [PubMed]

337. Li, J.; Hm, W.; Zhou, R.L.; Liu, G.J.; Dong, B.R. Huperzine A for Alzheimer’s Disease. *Cochr. Database Syst. Rev.* 2009. 2. [CrossRef]

338. Wang, R.; Can, X. Neuroprotective Effects of Huperzine A. *Neurosignals 2005, 14, 71–82.* [CrossRef]

339. Damar, U.; Gersner, R.; Johnstone, J.T.; Schachter, S.; Rotenberg, A.; Gersner, R.; Johnstone, J.T.; Schachter, S.; Rotenberg, A. Expert Review of Neurotherapeutics Huperzine A as a Neuroprotective and Antiepileptic Drug: A Review of Preclinical Research. *Expert Rev. Neurother.* 2016, 16, 671–680. [CrossRef]

340. Park, S. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhangjiang Hi-Tech Park, Shanghai, P.R. China. *J. Neurochem.* 2008, 1594–1603. [CrossRef]

341. Shuan, L.; Zhou, J.; Mei, X.; Can, X. Huperzine A Attenuates Cognitive Deficits and Brain Injury in Neonatal Rats after Hypoxia—Ischemia. *Brain Res. 2002, 949, 162–170.*